

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/005527 A1

(51) International Patent Classification⁷: C12P 13/04, C12N 9/02, 9/10, 9/88, 1/20, 15/10, C07H 21/04

(74) Agents: HANLEY, Elizabeth, A. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(21) International Application Number:
PCT/US2002/021336

(81) Designated States (*national*): AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 July 2002 (03.07.2002)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

Published:

— with international search report

(26) Publication Language: English

(71) Applicant (*for all designated States except US*): BASF AKTIENGESELLSCHAFT [DE/DE]; 67056 Ludwigshafen (DE).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): YOCUM, R., Rogers [US/US]; 4 Orchard Lane, Lexington, MA 02420 (US). PATTERSON, Thomas, A. [US/US]; 89 Church Street, Attleboro, MA 02760 (US). PERO, Janice, G. [US/US]; 20 Solomon Pierce Road, Lexington, MA 02420 (US). HERMANN, Theron [US/US]; 18 Chilhowie Drive, Kinnelon, NJ 07405 (US).

WO 2004/005527 A1

(54) Title: MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

(57) Abstract: The present invention features improved methods for the enhanced production of pantoate and pantothenate utilizing microorganisms having modified pantothenate biosynthetic enzyme activities and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities. In particular, the invention features methods for enhancing production of desired products by increasing levels of a key intermediate, ketopantoate, by increasing enzymes or substrates that contribute directly or indirectly to its synthesis. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

Related Applications

5 This application is related to International Patent Application No. PCT/US02/00925, entitled "Microorganisms and Processes for Enhanced Production of Pantothenate", filed January 18, 2002 (pending), and to International Patent Application No. PCT/US00/25993, entitled "Methods and Microorganisms for Production of Pantocompounds", filed September 21, 2000 (expired). The entire content of the above-
10 referenced applications is incorporated herein by this reference.

Background of the Invention

Pantothenate, also known as pantothenic acid or vitamin B5, is a member of the B complex of vitamins and is a nutritional requirement for mammals, including
15 livestock and humans (e.g., from food sources, as a water soluble vitamin supplement or as a feed additive). In cells, pantothenate is used primarily for the biosynthesis of coenzyme A (CoA) and acyl carrier protein (ACP). These coenzymes function in the metabolism of acyl moieties which form thioesters with the sulphydryl group of the 4'-phosphopantetheine portion of these molecules. These coenzymes are essential in all
20 cells, participating in over 100 different intermediary reactions in cellular metabolism.

The conventional means of synthesizing pantothenate (in particular, the bioactive D isomer) is *via* chemical synthesis from bulk chemicals, a process which is hampered by excessive substrate cost as well as the requirement for optical resolution of racemic intermediates. Accordingly, researchers have recently looked to bacterial or
25 microbial systems that produce enzymes useful in pantothenate biosynthesis processes (as bacteria are themselves capable of synthesizing pantothenate). In particular, bioconversion processes have been evaluated as a means of favoring production of the preferred isomer of pantothenic acid. Moreover, methods of direct microbial synthesis have recently been examined as a means of facilitating D-pantothenate production.

30 There is still, however, significant need for improved pantothenate production processes, in particular, for microbial processes optimized to produce higher yields of desired product.

Summary of the Invention

35 The present invention relates to improved processes (e.g., microbial syntheses) for the production of pantothenate. Pantothenate production processes have been described in related applications which feature, for example, microbes engineered to overexpress key enzymes of the pantothenate biosynthetic pathway and the

isoleucine-valine biosynthetic pathway (see e.g., Figure 1). Strains have been engineered that are capable of producing > 50 g/l of pantothenate in standard fermentation processes (see e.g., International Public. No. WO 01/21772 and U.S. Patent Application No. 60/262,995). In particular, increasing the expression of the *panB*, *panC*, 5 *panD* and *panE1* genes and increasing the expression of the *ilvBNC* and *ilvD* genes results in strains that convert glucose (pyruvate) to commercially attractive quantities of pantothenate.

In order to enhance production levels of for example, pantothenate, various improvements on the above-described methods have now been developed. For 10 example, U.S. Patent Application Serial No. 09/667,569 describes production strains having modified (e.g., deleted or decreased-activity) pantothenate kinase enzymes. In such strains, the pantothenate levels are effectively increased by decreasing utilization of pantothenate for coenzymeA (“CoA”) synthesis. U.S. Patent Application Serial No. 60/262,995 further describes improved pantothenate-production strains that have been 15 engineered to minimize utilization of various pantothenate biosynthetic enzymes and/or isoleucine-valine biosynthetic enzymes and/or their respective substrates from being used to produce an alternative product identified as [R]-3-(2-hydroxy-3-methylbutyrylamino)-propionic acid (“HMBPA”).

The present invention features methods to further enhance pantothenate 20 production by modulating a biosynthetic pathway that supplies a substrate for the pantothenate biosynthetic pathway, namely the methylenetetrahydrofolate (“MTF”) biosynthetic pathway. In particular, it has been discovered that increasing levels of MTF by modification of the MTF biosynthetic pathway results in enhanced levels of the key 25 pantothenate biosynthetic pathway intermediate, ketopantoate. Enhanced ketopantoate levels, in turn, result in significantly enhanced pantothenate production levels in appropriately engineered strains. In essence, the present inventors have identified a limiting step in the production of panto-compounds (e.g., pantothenate) by strains 30 engineered to overexpress, for example, the *panB*, *panC*, *panD*, *panE1*, *ilvBNC* and *ilvD* genes, and describe herein a means for overcoming this limitation by modification of the MTF biosynthetic pathway.

At least three effective means of modifying the MTF biosynthetic pathway are described herein. In one aspect, it has been demonstrated that increasing serine levels in the culture medium of pantothenate-producing microorganisms results in enhanced panto-compound production. It has also been demonstrated that increasing the 35 synthesis or activity of 3-phosphoglycerate dehydrogenase (the *serA* gene product), or the synthesis or activity of serine hydroxymethyl transferase (the *glyA* gene product), thereby enhancing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms, increases panto-compound production. Increased synthesis

of 3-phosphoglycerate dehydrogenase (the *serA* gene product) is achieved, for example, by overexpressing *serA* from an appropriately-engineered expression cassette. Increased synthesis of serine hydroxymethyl transferase (the *glyA* gene product) is achieved, for example, by overexpressing *glyA* from an appropriately-engineered expression cassette.

5 Alternatively, levels of serine hydroxymethyl transferase (the *glyA* gene product) are increased by altering the regulation of the *glyA* gene. For example, mutation or deletion of the gene encoding a negative regulator (*i.e.*, repressor) of *glyA* expression, the *purR* gene, effectively increases *glyA* expression. Additional methods suitable for increasing MTF levels in panto-compound producing microorganisms involve deregulating enzymes

10 responsible for converting glycine to MTF (*e.g.*, glycine cleavage enzymes).

Accordingly, in one aspect the invention features processes for the enhanced production of pantoate and pantothenate that involve culturing microorganisms having modified pantothenate biosynthetic enzyme activities and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities under conditions such

15 that pantothenate production is enhanced. In another aspect the invention features processes for the enhanced production of pantoate and pantothenate that involve culturing microorganisms having modified pantothenate biosynthetic enzyme activities, having modified isoleucine-valine (*ilv*) biosynthetic enzymes, and having modified methylenetetrahydrofolate (MTF) biosynthetic enzyme activities under conditions such

20 that pantothenate production is enhanced. In particular, the invention features methods for enhancing production of desired products (*e.g.*, pantoate and/or pantothenate) by increasing the levels of a key intermediate, ketopantoate, by enzymes that contribute to its synthesis. Preferred methods result in production of pantothenate at levels greater than 50, 60, 70 or more g/L after 36 hours of culturing the microorganisms, or such that

25 at least 60, 70, 80, 90, 100, 110, 120 or more g/L pantothenate is produced after 36 hours of culturing the microorganisms. Recombinant microorganisms and conditions for culturing same are also featured. Also featured are compositions produced by such microorganisms.

30 Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 is a schematic representation of the pantothenate and isoleucine-valine (*ilv*) biosynthetic pathways. Pantothenate biosynthetic enzymes are depicted in bold and their corresponding genes indicated in italics. Isoleucine-valine (*ilv*) biosynthetic enzymes are depicted in bold italics and their corresponding genes indicated in italics.

Figure 2 is a schematic representation of the methylenetetrahydrofolate (“MTF”) biosynthetic pathway in *E. coli* (and presumably in *B. subtilis*).

Figure 3 is a schematic representation of the construction of the plasmid pAN665.

5 Figure 4 is a schematic representation of the construction of the plasmid pAN670.

Figure 5 is a schematic representation of the plasmid pAN004.

Figure 6 is a schematic representation of the plasmid pAN396.

Figure 7 is a schematic representation of the plasmid pAN393.

10 Figure 8 is a schematic representation of the structure of pAN835F, a clone of the *B. subtilis purR* gene.

Figure 9 is a schematic representation of the structure of pAN838F, a plasmid designed to install a disruption of the *B. subtilis purR* gene.

15 Figure 10 is a schematic representation of the structure of pAN821, a plasmid designed to delete a portion of the *serA* gene, selecting for kanamycin resistance.

Figure 11 is a schematic representation of the structure of pAN824, a plasmid designed to integrate a non-amplifiable *P₂₆ serA* cassette at the *serA* locus, selecting for *Ser⁺*.

20 Figure 12 is a schematic representation of the structure of pAN395, a medium copy plasmid designed to integrate and amplify a *P₂₆ serA* expression cassette at the *serA* locus.

Detailed Description of the Invention

25 The present invention is directed to improved methods for producing panto-compounds (e.g., ketopantoate, pantoate and/or pantothenate) and strains engineered for use in said improved methods. Strains capable of producing > 50 g/l of pantothenate can be constructed as taught in International Patent Application Serial No. WO 01/21772 and in U.S. Patent Application Serial No. 60/262,995. By increasing the 30 expression of the *panB*, *panC*, *panD* and *panE1* genes and by increasing the expression of the *ilvBNC* and *ilvD* genes, one can design strains (e.g., *Bacillus* strains) that convert glucose (pyruvate) to commercially attractive quantities of pantothenate.

However, it has now been discovered that in strains engineered to express high levels of the *panB* gene product, ketopantoate hydroxymethyltransferase (e.g., 35 PA824, described in U.S. Patent Application Serial No. 09/667,569 and PA668-24, described in U.S. Patent Application Serial No. 60/262,995), a limiting step for further increases in the production of pantothenate is still the conversion of α-ketoisovalerate (α-KIV) to ketopantoate. Methods to increase the synthesis of α-KIV were described

previously in International Patent Application Serial No. WO 01/21772 and U.S. Patent Application Serial No. 60/262,995. Here we disclose that even further increases in pantothenate production can be achieved by engineering panto-compound producing microorganisms such that the level of MTF, or the rate of MTF synthesis is enhanced or increased.

Accordingly, the present invention features methods for improving panto-compound production that involve modulating the methylenetetrahydrofolate (“MTF”) biosynthetic pathway. In particular, increasing MTF levels in panto-compound producing microbes is an effective means of enhancing ketopantoate production, and in turn results in enhanced pantoate and/or pantothenate production in appropriately-engineered recombinant microorganisms.

Ketopantoate hydroxymethylenetransferase catalyzes the production of ketopantoate from α -ketoisovalerate (“ α -KIV”) and MTF (see e.g., Figure 1). In particular, the enzyme catalyzes the transfer of a hydroxymethyl group from MTF to α -KIV to yield ketopantoate. Both α -KIV and MTF are substrates for this reaction, and their syntheses can be increased in order to improve production of ketopantoate. The pathway for MTF biosynthesis in *E. coli* (and also in *Bacillus subtilis*) is outlined in Figure 2. MTF is synthesized from tetrahydrofolate and serine in a reaction catalyzed by the *glyA* gene that encodes serine hydroxymethyl transferase. For improved MTF synthesis the cells need increased quantities of both substrates and the product of the *glyA* gene.

In one embodiment, the invention features processes for the enhanced production of pantothenate that involve culturing a microorganism having (i) a deregulated pantothenate biosynthetic pathway (e.g., having one, two, three or four pantothenate biosynthetic enzymes deregulated) and (ii) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway (e.g., having at least one or two MTF biosynthetic enzymes deregulated), under conditions such that pantothenate production is enhanced. Exemplary pantothenate biosynthetic enzymes include ketopantoate hydroxymethyltransferase, ketopantoate reductase, pantothenate synthetase and aspartate- α -decarboxylase. Exemplary MTF biosynthetic enzymes include the *serA* gene product and the *glyA* gene product.

In another embodiment, the invention features processes for the enhanced production of pantothenate that involve culturing a microorganism having (i) a deregulated pantothenate biosynthetic pathway (e.g., having one, two, three or four pantothenate biosynthetic enzymes deregulated), (ii) a deregulated isoleucine-valine (*ilv*) biosynthetic pathway (e.g., having one, two or three *ilv* biosynthetic enzymes deregulated), and (iii) a deregulated MTF biosynthetic pathway (e.g., having at least one or two MTF biosynthetic enzymes deregulated), under conditions such that pantothenate

production is enhanced. Exemplary *ilv* biosynthetic enzymes include acetohydroxyacid acid synthetase, acetohydroxyacid isomeroreductase, and dihydroxyacid dehydratase.

In another embodiment, the invention features processes for the production of pantothenate that involve culturing a microorganism having a deregulated 5 pantothenate biosynthetic pathway, a deregulated *ilv* biosynthetic pathway, and a deregulated MTF biosynthetic pathway, such that at least 50 g/L pantothenate is produced after 36 hours of culturing the microorganism, preferably such that at least 60 g/L pantothenate is produced after 36 hours of culturing the microorganism, more preferably such that at least 70 g/L pantothenate is produced after 36 hours of culturing 10 the microorganism, and most preferably such that at least 80 g/L pantothenate, at least 90 g/L pantothenate, at least 100 g/L pantothenate, at least 110 g/L pantothenate, or at least 120 g/L pantothenate (or more) is produced after 36 hours of culturing the microorganism.

In another embodiment, the invention features processes for the 15 production of pantothenate that involve culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated *ilv* biosynthetic pathway, and a deregulated MTF biosynthetic pathway, deregulated such that at least 70 g/L pantothenate is produced after 48 hours of culturing the microorganism, preferably such that at least 80 g/L pantothenate is produced after 48 hours of culturing the 20 microorganism, and more preferably such that at least 90 g/L pantothenate is produced after 48 hours of culturing the microorganism.

In one exemplary embodiment, deregulation of the MTF biosynthetic pathway is achieved by deregulating the *serA* gene product in a panto-compound producing strain, for example, by expressing the *serA* gene constitutively or by 25 introducing a feedback resistant allele of *serA*. In another exemplary embodiment, deregulation of the MTF biosynthetic pathway is achieved by deregulating the *glyA* gene product in a panto-compound producing strain, for example, by overexpressing the *glyA* gene or modulating repression of the *glyA* gene by mutating or disrupting the *purR* gene product. In other exemplary embodiments, MTF biosynthesis is modulated by 30 increasing serine in the culture medium or deregulating glycine cleavage enzymes.

The invention further features methods as described above, wherein pantothenate production is further enhanced by regulating pantothenate kinase activity (e.g., wherein pantothenate kinase activity is decreased). In one embodiment, CoA is deleted and CoaX is downregulated. In another embodiment, CoaX is deleted and CoA 35 is downregulated. In yet another embodiment, CoaX and CoA are downregulated. The invention further features methods as described above, wherein the microorganisms are cultured under conditions of excess serine. The invention further features methods as

described above, wherein the microorganisms have the pantothenate biosynthetic pathway deregulated such that pantothenate production is independent of β-alanine feed.

Products synthesized according to the processes of the invention are also featured, as are compositions that include pantothenate produced according to said processes. Recombinant microorganisms for use in the processes of the invention are also featured. In one embodiment, the invention features a recombinant microorganism for the enhanced production of pantothenate having a deregulated pantothenate biosynthetic pathway and a deregulated MTF biosynthetic pathway. In another embodiment, the invention features a recombinant microorganism for the enhanced 10 production of pantothenate having a deregulated pantothenate biosynthetic pathway, a deregulated MTF biosynthetic pathway and a deregulated *ilv* pathway. Microorganisms can further have reduced pantothenate kinase activity. Preferred microorganisms belong to the genus *Bacillus*, for example *Bacillus subtilis*.

As described above, certain aspects of the invention feature processes for 15 the enhanced production of panto-compounds (e.g., pantoate and/or pantothenate) that involve culturing microorganisms having at least a deregulated pantothenate biosynthetic pathway. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway involving pantothenate biosynthetic enzymes (e.g., polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (e.g., substrates, 20 intermediates or products), cofactors and the like utilized in the formation or synthesis of pantothenate. The term "pantothenate biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of pantothenate in microorganisms (e.g., *in vivo*) as well as the biosynthetic pathway leading to the synthesis of pantothenate *in vitro*.

As used herein, a microorganism "having a deregulated pantothenate 25 biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (e.g., overexpressed) (both terms as defined herein) such that pantothenate production is enhanced (e.g., as compared to pantothenate production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). The term "pantothenate" includes the free 30 acid form of pantothenate, also referred to as "pantothenic acid" as well as any salt thereof (e.g., derived by replacing the acidic hydrogen of pantothenate or pantothenic acid with a cation, for example, calcium, sodium, potassium, ammonium, magnesium), also referred to as a "pantothenate salt". The term "pantothenate" also includes alcohol derivatives of pantothenate. Preferred pantothenate salts are calcium pantothenate or 35 sodium pantothenate. A preferred alcohol derivative is pantothenol. Pantothenate salts and/or alcohols of the present invention include salts and/or alcohols prepared *via* conventional methods from the free acids described herein. In another embodiment, a pantothenate salt is synthesized directly by a microorganism of the present invention. A

pantothenate salt of the present invention can likewise be converted to a free acid form of pantothenate or pantothenic acid by conventional methodology. The term "pantothenate" is also abbreviated as "pan" herein.

Preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (e.g., overexpressed) such that pantothenate production is 1 g/L or greater. More preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (e.g., overexpressed) such that 10 pantothenate production is 2 g/L or greater. Even more preferably, a microorganism "having a deregulated pantothenate biosynthetic pathway" includes a microorganism having at least one pantothenate biosynthetic enzyme deregulated (e.g., overexpressed) such that pantothenate production is 10 g/L, 20 g/L, 30 g/L, 40 g/L, 50 g/L, 60 g/L, 70 g/L, 80 g/L, 90 g/L, or greater.

15 The term "pantothenate biosynthetic enzyme" includes any enzyme utilized in the formation of a compound (e.g., intermediate or product) of the pantothenate biosynthetic pathway. For example, synthesis of pantoate from α -ketoisovalerate (α -KIV) proceeds *via* the intermediate, ketopantoate. Formation of ketopantoate is catalyzed by the pantothenate biosynthetic enzyme PanB or ketopantoate 20 hydroxymethyltransferase (the *panB* gene product). Formation of pantoate is catalyzed by the pantothenate biosynthetic enzyme PanE1 or ketopantoate reductase (the *panE1* gene product). Synthesis of β -alanine from aspartate is catalyzed by the pantothenate biosynthetic enzyme PanD or aspartate- α -decarboxylase (the *panD* gene product). Formation of pantothenate from pantoate and β -alanine (e.g., condensation) is catalyzed 25 by the pantothenate biosynthetic enzyme PanC or pantothenate synthetase (the *panC* gene product). Pantothenate biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at 30 least one pantothenate biosynthetic enzyme deregulated (e.g., deregulated such that pantothenate production is enhanced), said enzyme being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced 35 production of pantothenate that includes culturing a microorganism having at least two pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -

decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least three pantothenate biosynthetic enzymes deregulated, said enzymes being selected, for example, from the group consisting of 5 PanB (or ketopantoate hydroxymethyltransferase), PanC (or pantothenate synthetase), PanD (or aspartate- α -decarboxylase), and PanE1 (or ketopantoate reductase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least four pantothenate biosynthetic enzymes deregulated, for example, a microorganism having PanB (or 10 PanD (or aspartate- α -decarboxylase), and PanE1 (or ketopantoate reductase) deregulated.

In another aspect, the invention features processes for the enhanced production of pantothenate that involve culturing microorganisms having a deregulated isoleucine-valine biosynthetic pathway. The term “isoleucine-valine biosynthetic 15 pathway” includes the biosynthetic pathway involving isoleucine-valine biosynthetic enzymes (e.g., polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (e.g., substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of conversion of pyruvate to valine or isoleucine. The term “isoleucine-valine biosynthetic pathway” includes the biosynthetic pathway leading to 20 the synthesis of valine or isoleucine in microorganisms (e.g., *in vivo*) as well as the biosynthetic pathway leading to the synthesis of valine or isoleucine *in vitro*.

As used herein, a microorganism “having a deregulated isoleucine-valine (*ilv*) pathway” includes a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (e.g., overexpressed) (both terms as defined herein) 25 such that isoleucine and/or valine and/or the valine precursor, α -ketoisovalerate (α -KIV) production is enhanced (e.g., as compared to isoleucine and/or valine and/or α -KIV production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism). Figure 1 includes a schematic representation 30 of the isoleucine-valine biosynthetic pathway. Isoleucine-valine biosynthetic enzymes are depicted in bold italics and their corresponding genes indicated in italics. The term “isoleucine-valine biosynthetic enzyme” includes any enzyme utilized in the formation 35 of a compound (e.g., intermediate or product) of the isoleucine-valine biosynthetic pathway. According to Figure 1, synthesis of valine from pyruvate proceeds *via* the intermediates, acetolactate, α,β -dihydroxyisovalerate (α,β -DHIV) and α -ketoisovalerate (α -KIV). Formation of acetolactate from pyruvate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid synthetase (the *ilvBN* gene products, or alternatively, the *alsS* gene product). Formation of α,β -DHIV from acetolactate is catalyzed by the isoleucine-valine biosynthetic enzyme acetohydroxyacid

isomeroreductase (the *ilvC* gene product). Synthesis of α -KIV from α,β -DHIV is catalyzed by the isoleucine-valine biosynthetic enzyme dihydroxyacid dehydratase (the *ilvD* gene product). Moreover, valine and isoleucine can be interconverted with their respective α -keto compounds by branched chain amino acid transaminases. Isoleucine-valine biosynthetic enzymes may also perform an alternative function as enzymes in the HMBPA biosynthetic pathway described herein.

Accordingly, in one embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least one isoleucine-valine (*ilv*) biosynthetic enzyme deregulated (e.g., deregulated such that valine and/or isoleucine and/or α -KIV production is enhanced), said enzyme being selected, for example, from the group consisting of IlvBN, AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, said enzyme being selected, for example, from the group consisting of IlvBN, AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase). In another embodiment, the invention features a process for the enhanced production of pantothenate that includes culturing a microorganism having at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated, for example, said microorganism having IlvBN or AlsS (or acetohydroxyacid synthetase), IlvC (or acetohydroxyacid isomeroreductase) and IlvD (or dihydroxyacid dehydratase) deregulated.

As mentioned herein, enzymes of the pantothenate biosynthetic pathway and/or the isoleucine-valine (*ilv*) pathway have been discovered to have an alternative activity in the synthesis of [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (“HMBPA”) or the [R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (“HMBPA”) biosynthetic pathway. The term “[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (“HMBPA”) biosynthetic pathway” includes the alternative biosynthetic pathway involving biosynthetic enzymes and compounds (e.g., substrates and the like) traditionally associated with the pantothenate biosynthetic pathway and/or isoleucine-valine (*ilv*) biosynthetic pathway utilized in the formation or synthesis of HMBPA. The term “HMBPA biosynthetic pathway” includes the biosynthetic pathway leading to the synthesis of HMBPA in microorganisms (e.g., *in vivo*) as well as the biosynthetic pathway leading to the synthesis of HMBPA *in vitro*.

The term “HMBPA biosynthetic enzyme” includes any enzyme utilized in the formation of a compound (e.g., intermediate or product) of the HMBPA biosynthetic pathway. For example, synthesis of 2-hydroxyisovaleric acid (α -HIV) from α -ketoisovalerate (α -KIV) is catalyzed by the *panE1* or *panE2* gene product (PanE1 is

alternatively referred to herein as ketopantoate reductase) and/or is catalyzed by the *ilvC* gene product (alternatively referred to herein as acetohydroxyacid isomeroreductase). Formation of HMBPA from β -alanine and α -HIV is catalyzed by the *panC* gene product (alternatively referred to herein as pantothenate synthetase).

5 The term “[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (“HMBPA”)” includes the free acid form of HMBPA, also referred to as “[R]-3-(2-hydroxy-3-methyl-butyrylamino)-propionate” as well as any salt thereof (e.g., derived by replacing the acidic hydrogen of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate with a cation, for example,

10 calcium, sodium, potassium, ammonium, magnesium), also referred to as a “3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid salt” or “HMBPA salt”. Preferred HMBPA salts are calcium HMBPA or sodium HMBPA. HMBPA salts of the present invention include salts prepared *via* conventional methods from the free acids described herein. An HMBPA salt of the present invention can likewise be converted to a free acid

15 form of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid or 3-(2-hydroxy-3-methyl-butyrylamino)-propionate by conventional methodology.

In preferred embodiments, the invention features processes for the enhanced production of panto-compounds (e.g., pantoate and/or pantothenate) that involve culturing a microorganism having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway. The term “methylenetetrahydrofolate (MTF) biosynthetic pathway” refers to the biosynthetic pathway involving MTF biosynthetic enzymes (e.g., polypeptides encoded by biosynthetic enzyme-encoding genes), compounds (e.g., substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of the PanB substrate, MTF. The term “methylenetetrahydrofolate (MTF) biosynthetic pathway” refers to the biosynthetic pathway leading to the synthesis of MTF *in vivo* (e.g., the pathway in *E. coli*, as depicted in Figure 2) as well as the biosynthetic pathway leading to the synthesis of MTF *in vitro*. The term “methylenetetrahydrofolate (MTF) biosynthetic enzyme” includes any enzyme utilized in the formation of a compound (e.g., intermediate or product) of the

20 methylenetetrahydrofolate (MTF) biosynthetic pathway.

25 The present invention is based, at least in part, on the discovery that deregulation of certain MTF biosynthetic enzymes results in enhanced production of MTF. A MTF biosynthetic enzyme, the deregulation of which results in enhanced MTF production, is termed a “MTF biosynthesis-enhancing enzyme”. Exemplary “MTF biosynthesis-enhancing enzymes” are the *serA* gene product (3-phosphoglycerate dehydrogenase) and the *glyA* gene product (serine hydroxymethyl transferase). A

30 microorganism “having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway”, is a microorganism having at least one MTF biosynthesis-enhancing enzyme

35 The present invention is based, at least in part, on the discovery that deregulation of certain MTF biosynthetic enzymes results in enhanced production of MTF. A MTF biosynthetic enzyme, the deregulation of which results in enhanced MTF production, is termed a “MTF biosynthesis-enhancing enzyme”. Exemplary “MTF biosynthesis-enhancing enzymes” are the *serA* gene product (3-phosphoglycerate dehydrogenase) and the *glyA* gene product (serine hydroxymethyl transferase). A

40 microorganism “having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway”, is a microorganism having at least one MTF biosynthesis-enhancing enzyme

deregulated (*e.g.*, overexpressed) such that MTF production or biosynthesis is enhanced (*e.g.*, as compared to MTF production in said microorganism prior to deregulation of said biosynthetic enzyme or as compared to a wild-type microorganism).

In one embodiment, the invention features a process for the enhanced
5 production of panto-compounds (*e.g.*, pantoate and/or pantothenate) that includes
culturing a microorganism having a deregulated “methylenetetrahydrofolate (MTF)
biosynthetic pathway”, as defined herein. In another embodiment, the invention features
a process for the enhanced production of panto-compounds (*e.g.*, pantoate and/or
pantothenate) that includes culturing a microorganism having a deregulated MTF
10 biosynthesis-enhancing enzyme. In preferred embodiments, the invention features
processes for the enhanced production of panto-compounds (*e.g.*, pantoate and/or
pantothenate) that includes culturing a microorganism having a deregulated *glyA* gene
product (serine hydroxymethyl transferase) and/or a deregulated *serA* gene product (3-
phosphoglycerate dehydrogenase).

15 Yet another aspect of the present invention features processes for the
enhanced production of pantothenate that include culturing microorganisms under
culture conditions selected to favor pantothenate production, for example, by culturing
microorganisms with excess serine (a *glyA* substrate) in the medium. The term “excess
serine” includes serine levels increased or higher than those routinely utilized for
20 culturing the microorganism in question. For example, culturing the *Bacillus*
microorganisms described in the instant Examples is routinely done in the presence of
about 0-2.5 g/L serine. Accordingly, excess serine levels can include levels of greater
than 2.5 g/L serine, for example, between about 2.5 and 10 g/L serine. Excess serine
levels can include levels of greater than 5 g/L serine, for example, between about 5 and
25 10 g/L serine.

Yet another aspect of the present invention features culturing the
microorganisms described herein under conditions such that pantothenate production is
further increased, for example, by increasing pantothenate and/or isoleucine-valine (*ilv*)
biosynthetic pathway precursors and/or intermediates as defined herein (*e.g.*, culturing
30 microorganisms in the presence of excess β-alanine, valine and/or α-KIV) or,
alternatively, further modifying said microorganisms such that they are capable of
producing significant levels of β-alanine in the absence of a β-alanine feed (*i.e.*, β-
alanine independent microorganisms, as described in U.S. Patent Application Serial No.
09/09/667,569).

35 Yet another aspect of the invention features further regulating
pantothenate kinase activity in pantothenate-producing strains such that pantothenate
production is enhanced. Pantothenate kinase is a key enzyme catalyzing the formation
of Coenzyme A (CoA) from pantothenate (see *e.g.*, U.S. Patent Application Serial No.

09/09/667,569). Regulation of pantothenate kinase (*e.g.*, decreasing the activity or level of pantothenate kinase) reduces the production of CoA, favoring pantothenate accumulation. In one embodiment, pantotheante kinase activity is decreased by deleting CoaA and downregulating CoaX activity (CoaA and CoaX are both capable of catalyzing the first step in CoA biosynthesis in certain microorganisms). In another embodiment, pantothenate kinase activity is decreased by deleting CoaX and downregulating CoaA. In yet another embodiment, pantotheante kinase activity is decreased by downregulating CoaA and CoaX activities.

10 Various aspects of the invention are described in further detail in the following subsections.

I. Targeting Genes Encoding Various Pantothenate and/or Isoleucine-Valine(*ilv*) and/or Methylenetetrahydrofolate (MTF) Biosynthetic Enzymes

15 In one embodiment, the present invention features modifying or increasing the level of various biosynthetic enzymes of the pantothenate and/or isoleucine-valine(*ilv*) and/or methylenetetrahydrofolate (MTF) biosynthetic pathways. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic 20 enzymes.

The term “gene”, as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism).
25 Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3’ end of a first gene overlapping the 5’ end of a second gene), the overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequeunces, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A
30 gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An “isolated gene”, as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences that encode a second or distinct protein, 35 adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated

gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences).

Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2

5 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a

10 promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to
15 give a single mRNA that encodes all of the proteins.

A "gene having a mutation" or "mutant gene" as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the

20 wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%,
25 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold greater than the activity of the polypeptide or protein encoded by
30 the wild-type gene.
35

In another embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a “reduced activity” or “reduced enzymatic activity” is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a “reduced activity” or “reduced enzymatic activity” can also include an activity that has been deleted or “knocked out” (*e.g.*, approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).

Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an activity of a protein in a crude cell extract or isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For example, assaying for a mutant gene (*i.e.*, said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is a temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an “increased enzymatic activity” can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a “reduced enzymatic activity” is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

It will be appreciated by the skilled artisan that even a single substitution in a nucleic acid or gene sequence (*e.g.*, a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type polypeptide or protein. A mutant gene (*e.g.*, encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a microorganism expressing said mutant gene or producing said mutant protein or

polypeptide (*i.e.*, a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue can have an identical or substantially similar activity, optionally phenotypically indiscernable when produced in a microorganism, as compared to a corresponding

5 microorganism expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (*e.g.*, 30-50% sequence identity)

10 sequence identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

It will also be appreciated by the skilled artisan that nucleic acid molecules, genes, protein or polypeptides for use in the instant invention can be derived from any microorganisms having a MTF biosynthetic pathway, an *ilv* biosynthetic pathway or a pantothenate biosynthetic pathway. Such nucleic acid molecules, genes, protein or polypeptides can be identified by the skilled artisan using known techniques such as homology screening, sequence comparison and the like, and can be modified by the skilled artisan in such a way that expression or production of these nucleic acid

20 molecules, genes, protein or polypeptides occurs in a recombinant microorganism (*e.g.*, by using appropriate promotors, ribosomal binding sites, expression or integration vectors, modifying the sequence of the genes such that the transcription is increased (taking into account the preferable codon usage), etc., according to techniques described herein and those known in the art).

25 In one embodiment, the genes of the present invention are derived from a Gram positive microorganism organism (*e.g.*, a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). The term "derived from" (*e.g.*, "derived from" a Gram positive microorganism) refers to a gene which is naturally found in the microorganism (*e.g.*, is naturally found in a Gram positive microorganism). In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornybacterium* (*e.g.*, *Cornybacterium glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism is of the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lenthimorbus*, *Bacillus lenthus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*,

Bacillus licheniformis, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term “derived from *Bacillus subtilis*” or “*Bacillus subtilis*-derived” includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis purR* genes, *serA* genes, *glyA* genes, *coaX* genes, *coaA* genes, *pan* genes and/or *ilv* genes.

In another embodiment, the genes of the present invention are derived from a Gram negative (excludes basic dye) microorganism. In a preferred embodiment, the genes of the present invention are derived from a microorganism belonging to a genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the genes of the present invention are derived from a microorganism of the genus *Escherichia*. In an even more preferred embodiment, the genes of the present invention are derived from *Escherichia coli*. In another embodiment, the genes of the present invention are derived from *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g., isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* pantothenate biosynthetic genes and/or isoleucine-valine (*ilv*) biosynthetic genes and/or methylenetetrahydrofolate (MTF) biosynthetic genes. The term “recombinant nucleic acid molecule” includes a nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase “operably linked to regulatory sequence(s)” means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g.,

enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (e.g., when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism).

5 The term “regulatory sequence” includes nucleic acid sequences which affect (e.g., modulate or regulate) expression of other nucleic acid sequences (i.e., genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it

10 appears in nature, e.g., in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (e.g., operably linked to “native” regulatory sequences (e.g., to the “native” promoter). Alternatively, a gene of interest can be included in a recombinant

15 nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (e.g., a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (e.g., other bacterial regulatory sequences, bacteriophage regulatory

20 sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (e.g., a sequence which has been modified, mutated, substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-
25 termination signals and other expression control elements (e.g., sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring
30 Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (e.g., constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (e.g., inducible promoters, for example, xylose inducible promoters) and those which attenuate or
35 repress expression of a nucleotide sequence in a microorganism (e.g., attenuation signals or repressor binding sequences, for example, a PurR binding site). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative

regulation of transcription can be removed such that expression of a gene of interest is enhanced.

In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a pantothenate biosynthetic enzyme, an isoleucine-valine biosynthetic enzyme and/or a methylenetetrahydrofolate (MTF) biosynthetic enzyme) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (e.g., bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (e.g., a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of *P₁₅*, *P₂₆* or *P_{veg}*, having for example, the following respective sequences:

GCTATTGACGACAGCTATGGTCAGTCCACCAACCAAAACTGTGCTCAGT
 ACCGCCAATATTCTCCCTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT
 CCACGCTGTGTAAAAATTACAAAAAGGTATTGACTTCCCTACAGGGTGT
 GTAATAATTAAATTACAGGCAGGGCAACCCCGCCTGT (SEQ ID NO:1),

GCCTACCTAGCTCCAAGAAAGATATCCTAACAGCACAAAGAGCGGAAAGAT
 GTTTGTTCTACATCCAGAACAAACCTCTGCTAAAATTCCCTGAAAAATTGCA
 AAAAGTTGTTGACTTATCTACAAGGTGTGGTATAATAATCTAACACAGC
 AGGACGC (SEQ ID NO:2), and

GAGGAATCATAGAATTGTCAAAATAATTATTGACAACGTCTTATTAAC

GTTGATATAATTAAATTATTGACAAAAATGGGCTCGTGTGTACAATA
 AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:3). Additional preferred promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus* (e.g., *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram positive microorganisms include, but are not limited to, *amy* and *SPO2* promoters. Additional preferred promoters, for example, for use in Gram negative microorganisms include, but are not limited to, *cos*, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3, *gal*, *trc*, *ara*, SP6, λ-PR or λ-PL.

In another embodiment, a recombinant nucleic acid molecule of the present invention includes a terminator sequence or terminator sequences (e.g., transcription terminator sequences). The term “terminator sequences” includes regulatory sequences that serve to terminate transcription of mRNA. Terminator

sequences (or tandem transcription terminators) can further serve to stabilize mRNA (*e.g.*, by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes sequences that allow for detection of the vector containing said sequences (*i.e.*, detectable and/or selectable markers), for example, genes that encode antibiotic resistance sequences or that overcome auxotrophic mutations, for example, *trpC*, drug markers, fluorescent markers, and/or colorimetric markers (*e.g.*, *lacZ*/ β -galactosidase). In yet another embodiment, a recombinant nucleic acid molecule of the present invention includes an artificial ribosome binding site (RBS) or a sequence that gets transcribed into an artificial RBS. The term “artificial ribosome binding site (RBS)” includes a site within an mRNA molecule (*e.g.*, coded within DNA) to which a ribosome binds (*e.g.*, to initiate translation) which differs from a native RBS (*e.g.*, a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22, 23-24, 25-26, 27-28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-15 or more differ from the native RBS (*e.g.*, the native RBS of a gene of interest, for example, the native *panB* RBS TAAACATGAGGAGGAGAAAACATG (SEQ ID NO:4) or the native *panD* RBS ATTCGAGAAATGGAGAGAATATAATATG (SEQ ID NO:5)). Preferably, nucleotides that differ are substituted such that they are identical to one or more nucleotides of an ideal RBS when optimally aligned for comparisons. Ideal RBSs include, but are not limited to, AGAAAGGAGGTGA (SEQ ID NO:6), TTAAGAAAGGAGGTGANNNNATG (SEQ ID NO:7), TTAGAAAGGAGGTGANNNNNATG (SEQ ID NO:8), AGAAAGGAGGTGANNNNNNNATG (SEQ ID NO:9), and 25 AGAAAGGAGGTGANNNNNNNATG (SEQ ID NO:10). Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panB*, for example, of *B. subtilis panB*) include CCCTCTAGAAGGAGGAGAAAACATG (SEQ ID NO:11) and 30 CCCTCTAGAGGAGGAGAAAACATG (SEQ ID NO:12). Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *panD*, for example, of *B. subtilis panD*) include TTAGAAAGGAGGATTAAATATG (SEQ ID NO:13), TTAGAAAGGAGGTTAATTAAATG (SEQ ID NO:14), TTAGAAAGGAGGTGATTAAATATG (SEQ ID NO:15), 35 TTAGAAAGGAGGTGTTAAAATG (SEQ ID NO:16), ATTCGAGAAAGGAGG TGAATATAATATG (SEQ ID NO:17), ATTCGAGAAAGGAGGTGAATAATAATG (SEQ ID NO:18), and ATTCGTAGAAAGGAGGTGAATTAAATATG (SEQ ID NO:19).

The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term “recombinant vector” includes a vector (*e.g.*, plasmid, phage, phasmid, virus, cosmid or other purified nucleic acid 5 vector) that has been altered, modified or engineered such that it contains greater, fewer or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for 10 example, promoter sequences, terminator sequences and/or artificial ribosome binding sites (RBSSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences function in *E. coli*. In another embodiment, replication-enhancing sequences are derived 15 from pBR322.

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term “antibiotic resistance sequences” includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are 20 selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo* (neomycin resistance) sequences, *kan* (kanamycin resistance) sequences and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (*e.g.*, sequences designed to allow 25 recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice 30 of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

III. Recombinant Microorganisms

The present invention further features microorganisms, *i.e.*, recombinant microorganisms, that include vectors or genes (*e.g.*, wild-type and/or mutated genes) as 35 described herein. As used herein, the term “recombinant microorganism” includes a microorganism (*e.g.*, bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (*e.g.*, genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (*e.g.*, when the genetic

modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Cornybacterium* (e.g., *Cornybacterium glutamicum*), *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lenthus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella* (e.g., *Salmonella typhimurium*), *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *Saccharomyces cerevisiae*).

A preferred “recombinant” microorganism of the present invention is a microorganism having a deregulated pantothenate biosynthesis pathway or enzyme, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway or enzyme and/or a modified or deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway or enzyme. The term “deregulated” or “deregulation” includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase “deregulated pathway” includes a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that

the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to “deregulate” a pathway (*e.g.*, to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (*e.g.*, two or 5 three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an “operon” (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of each gene product encoded by the operon. Alteration or modification of a 10 regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of a gene or operon, altering nucleic acid sequences adjacent to a gene or operon (or within an operon) such as a ribosome 15 binding site, increasing the copy number of a gene or operon, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a gene or operon and/or translation of a gene product or gene products of a gene or operon, respectively, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of 20 antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is 25 designed or engineered such that at least one pantothenate biosynthetic enzyme, at least one isoleucine-valine biosynthetic enzyme, and/or at least one MTF biosynthetic enzyme is overexpressed. The term “overexpressed” or “overexpression” includes expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not 30 been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or 35 modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a

particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

IV. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (*e.g.*, maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (*e.g.*, a sterile, liquid medium) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (*e.g.*, carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy meal, soy flour, soy grits, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, growth promoters and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product (*e.g.*, pantoate and/or pantothenate). In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment,

microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration

5 (e.g., oxygen) to result in production of the desired product (e.g., pantoate and/or pantothenate). In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or
10 shaking the culture vessel (e.g., tube or flask) or by various pumping equipment.

Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (e.g., via addition of antifoaming agents).

15 Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (e.g., pantoate and/or pantothenate). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between
20 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (e.g., maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (e.g., rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (e.g., a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation.
30 The phrase "batch process" or "batch fermentation" refers to a system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-
35 batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (e.g., added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation

media is added continuously to a fermentor and an equal amount of used or “conditioned” media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, pantoate and/or pantothenate). A variety of such processes have been developed and are well-known in the art.

5 The phrase “culturing under conditions such that a desired compound is produced” includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the
10 desired amount of a compound (*e.g.*, pantoate and/or pantothenate). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a time sufficient to reach a suitable concentration of pantoate and/or pantothenate or suitable ratio of pantoate and/or pantothenate:HMBPA). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment,
15 culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 10 g/L of compound are produced in about 36 hours, at least about 10 to 20 g/L compound are produced in about 48 hours, or at least about 20 to 30 g/L compound in
20 about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 5 to 20 g/L of compound are produced in about 36 hours, at least about 20 to 30 g/L compound are produced in about 48 hours, or at least about 30 to 50 or 60 g/L compound in about 72 hours. In yet another embodiment, microorganisms are cultured under conditions such that at least about 40 to 60 g/L of
25 compound are produced in about 36 hours, or at least about 60 to 90 g/L compound are produced in about 48 hours. It will be appreciated by the skilled artisan that values above the upper limits of the ranges recited may be obtainable by the processes described herein, for example, in a particular fermentation run or with a particular engineered strain.

30

Preferably, a production method of the present invention results in production of a level of pantothenate that is “enhanced as compared to an appropriate control”. The term “appropriate control”, as defined herein, includes any control recognized by the skilled artisan as being appropriate for determining enhanced, increased, or elevated levels of desired product. For example, where the process features culturing a microorganism having a deregulated pantothenate biosynthetic pathway and said microorganism further has a deregulated MTF biosynthetic pathway (*i.e.*, has been engineered such that at least one MTF biosynthetic enzyme is deregulated, for example,

overexpressed) an appropriate control includes a culture of the microorganism before or absent manipulation of the MTF enzyme or pathway (*i.e.*, having only the pantothenate biosynthetic pathway deregulated). Likewise, where the process features culturing a microorganism having a deregulated pantothenate biosynthetic pathway and a 5 deregulated *ilv* biosynthetic pathway and said microorganism further has a deregulated MTF biosynthetic pathway (*i.e.*, has been engineered such that at least one MTF biosynthetic enzyme is deregulated, for example, overexpressed) an appropriate control includes a culture of the microorganism before or absent manipulation of the MTF enzyme or pathway (*i.e.*, having only the pantothenate biosynthetic pathway and *ilv* 10 biosynthetic pathway deregulated). Comparison need not be performed in each process practiced according to the present invention. For example, a skilled artisan can determine appropriate controls empirically from performing a series of reactions (*e.g.*, test tube cultures, shake flask cultures, fermentations), for example, under the same or similar conditions. Having appreciated a routine production level, for example, by a 15 particular strain, the artisan is able to recognize levels that are enhanced, increased or elevated over such levels. In other words, comparison to an appropriate control includes comparison to a predetermined values (*e.g.*, a predetermined control).

Thus, in an embodiment wherein an appropriately engineered strain produces 40 g/L pantothenate in 36 hours (prior to manipulation such that pantothenate 20 production is enhanced), production of 50, 60, 70 or more g/L pantothenate (after manipulation, for example, manipulation such that at least one MTF biosynthetic enzyme is overexpressed) exemplifies enhanced production. Likewise, in an embodiment wherein an appropriately engineered strain produces 50 g/L pantothenate in 48 hours (prior to manipulation such that pantothenate production is enhanced), 25 production of 60, 70, 80, 90 or more g/L pantothenate (after manipulation, for example, manipulation such that at least one MTF biosynthetic enzyme is overexpressed) exemplifies enhanced production.

The methodology of the present invention can further include a step of recovering a desired compound (*e.g.*, pantoate and/or pantothenate). The term 30 “recovering” a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*, anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional 35 adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For example, a compound

can be recovered from culture media by first removing the microorganisms from the culture. Media are then passed through or over a cation exchange resin to remove cations and then through or over an anion exchange resin to remove inorganic anions and organic acids having stronger acidities than the compound of interest. The resulting 5 compound can subsequently be converted to a salt (*e.g.*, a calcium salt) as described herein.

Preferably, a desired compound of the present invention is “extracted”, “isolated” or “purified” such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts).
10 The language “substantially free of other media components” includes preparations of the desired compound in which the compound is separated from media components or fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more
15 preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation
20 byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.
25

In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or
30 culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

In yet another embodiment, the desired compound is partially purified. The term “partially purified” includes media preparations that have had at least some processing, for example, treatment (*e.g.*, batch treatment) with a commercial resin. In
35 preferred embodiments, the “partially purified” preparation has greater than about 30% (by dry weight) of the desired compound, preferably greater than about 40% of the desired compound, more preferably greater than about 50% of the desired compound, still more preferably greater than about 60% of the desired compound, and most

preferably greater than about 70% desired compound. "Partially purified" preparations also preferably have 80% or less (by dry weight) of the desired compound (*i.e.*, are less pure than "extracted", "isolated" or "purified" preparations, as defined herein).

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is aspartate. In another embodiment, the biosynthetic precursor or precursor is β -alanine. The amount of aspartate or β -alanine added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of pantoate and/or pantothenate). Biosynthetic precursors of the present invention can be added in the form of a concentrated solution or suspension (*e.g.*, in a suitable solvent such as water or buffer) or in the form of a solid (*e.g.*, in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time. The term "excess β -alanine" includes β -alanine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L β -alanine. Accordingly, excess β -alanine levels can include levels of about 0.01-1, preferably about 1-20 g/L.

In yet another embodiment, the biosynthetic precursor is valine. In yet another embodiment, the biosynthetic precursor is α -ketoisovalerate. Preferably, valine or α -ketoisovalerate is added in an amount that results in a concentration in the medium sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. The term "excess α -KIV" includes α -KIV levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.01 g/L α -KIV. Accordingly, excess α -KIV levels can include levels of about 0.01-1, preferably about 1-20 g/L α -KIV. The term "excess valine" includes valine levels increased or higher than those routinely utilized for culturing the microorganism in question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-0.5 g/L valine. Accordingly, excess valine levels can include levels of about 0.5-5 g/L, preferably about 5-20 g/L valine.

In yet another embodiment, the biosynthetic precursor is serine.

Preferably, serine is added in an amount that results in a concentration in the medium sufficient for production of the desired product (*e.g.*, pantoate and/or pantothenate) to occur. Excess serine (as defined herein) can also be added according to the production processes described herein, for example, for the enhanced production of pantothenate. The skilled artisan will appreciate that extreme excesses of biosynthetic precursors can result in microorganism toxicity. Biosynthetic precursors are also referred to herein as "supplemental biosynthetic substrates".

Another aspect of the present invention includes biotransformation processes which feature the recombinant microorganisms described herein. The term "biotransformation process", also referred to herein as "bioconversion processes", includes biological processes which results in the production (*e.g.*, transformation or conversion) of appropriate substrates and/or intermediate compounds into a desired product.

The microorganism(s) and/or enzymes used in the biotransformation reactions are in a form allowing them to perform their intended function (*e.g.*, producing a desired compound). The microorganisms can be whole cells, or can be only those portions of the cells necessary to obtain the desired end result. The microorganisms can be suspended (*e.g.*, in an appropriate solution such as buffered solutions or media), rinsed (*e.g.*, rinsed free of media from culturing the microorganism), acetone-dried, immobilized (*e.g.*, with polyacrylamide gel or k-carrageenan or on synthetic supports, for example, beads, matrices and the like), fixed, cross-linked or permeabilized (*e.g.*, have permeabilized membranes and/or walls such that compounds, for example, substrates, intermediates or products can more easily pass through said membrane or wall).

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

EXAMPLES

Example I: Panto-Compound Production Strains

In developing *Bacillus* strains for the production of pantothenate, various 5 genetic manipulations are made to genes and enzymes involved in the pantothenate biosynthetic pathway and the isoleucine-valine (*ilv*) pathway (Figure 1) as described in U.S. Patent Application Serial No. 09/400,494 and U.S. Patent Application Serial No. 09/667,569. For example, strains having a deregulated *panBCD* operon and/or having deregulated *panE1* exhibit enhanced pantothenate production (when cultured in the 10 presence of β-alanine and α-ketoisovalerate (α-KIV)). Strains further deregulated for *ilvBNC* and *ilvD* exhibit enhanced pantothenate production in the presence of only β-alanine. Moreover, it is possible to achieve β-alanine independence by further deregulating *panD*.

An exemplary pantothenate production strain is PA824, a tryptophan 15 prototroph, Spec and Tet resistant, deregulated for *panBCD* at the *panBCD* locus, deregulated for *panE1* at the *panE1* locus (two genes in the *B. subtilis* genome are homologous to *E. coli panE*, *panE1* and *panE2*, the former encoding the major ketopantoate reductase involved in pantothenate production, while *panE2* does not contribute to pantothenate synthesis (U.S. Patent Application Serial No. 09/400,494), 20 deregulated for *ilvD* at the *ilvD* locus, overexpressing an *ilvBNC* cassette at the *amyE* locus, and overexpressing *panD* at the *bpr* locus. PA824 routinely yields approximately 40-50 g/L pantothenate, when cultured for 48 hours in 14 L fermentor vessels according to standard fermentation procedures (see e.g., provisional Patent Application Serial No. 60/263,053 or provisional Patent Application Serial No. 60/262,995, incorporated by 25 reference herein). Briefly, batch media (4.5 L) containing trace elements is inoculated with shake flask cultures of PA824. The fermentations are controlled for temperature (e.g., 43°C), dissolved O₂, and pH, and are run as a glucose limited fed batch process. After the initial batched glucose is consumed, glucose concentrations are maintained between about 0 and 1 g/L by continuous feeding of fresh FEED media. pH is set at 7.2, 30 monitored, and maintained by feeding either a NH₃- or a H₃PO₄-solution. The dissolved oxygen concentration [pO₂] is maintained at about 10-30% by regulation of the agitation and aeration rate. Foaming is controlled by addition of an appropriate antifoam agent. The pantothenate titer in the fermentation broth is determined (by HPLC analysis) after removal of the cells by centrifugation.

35 A second exemplary strain is PA668. PA668 is a derivative of PA824 that contains extra copies of *P26 panB* amplified at the *vpr* and/or *panB* locus. PA668 was constructed using a *panB* expression vector (pAN636) which allows for selection of multiple copies using chloramphenicol. Briefly, a pAN636 *NotI* restriction fragment

(excluding vector sequences) was ligated and then used to transform PA824 with selection on plates containing 5 µg/ml chloramphenicol. Transformants resistant to 30 µg/ml chloramphenicol were isolated and screened for pantothenate production in 48 hour test tube cultures. The isolates produce about 10 percent more pantothenate than PA824. In 10-L fermentations, a first strain, PA668-2A, produces pantothenate in amounts comparable to PA824 cultured under similar conditions (e.g., ~45-50 g/L at 36 hours). After 36 hours, when pantothenate production routinely begins to slow with PA824, PA668-2A continues to produce significant levels of pantothenate (e.g., ~ 60-65 g/l pantothenate at 48 hours). A second strain, PA668-24, produces pantothenate at an even faster rate, reaching 60-70 g/L after 48 hours.

A third production strain, PA721B-39, was engineered to further include an amplifiable *P26 panBpanD* cassette as follows. First, a single expression cassette was constructed that is capable of integrating both *panB* and *panD* at the *bpr* locus. Combining both genes into one expression cassette simplifies the resulting strain by eliminating an antibiotic resistance marker. The *P26 panBpanD* expression cassette was constructed to include each of two different *panD* ribosome binding sites (the RBSs having previously been synthesized and tested in International Public. No. WO 01/21772 and U.S. Patent Application No. 60/262,995). The cassette further included the synthetic *panB* gene ribosome binding site (RBS1), but the design permits future alteration of the *panB* RBS by simple oligonucleotide cassette substitution. In the first step of construction, the *panB* gene was joined to the two *panD* gene cassettes as illustrated in Figure 3 for the construction of pAN665. Next, the resulting *panBpanD* cassettes were transferred to *B. subtilis* expression vector pOTP61 as illustrated in Figure 4. A summary of the essential features of each plasmid (pAN670 and pAN674) constructed is presented in Table 1.

Table 1. Plasmids containing various *B. subtilis panBpanD* gene expression cassettes.

Plasmid	<i>panD</i> RBS	Vector	Host strain
pAN665	Standard	pASK-1BA3	<i>E. coli</i>
pAN670	"	pOTP61	<i>B. subtilis</i>
pAN669	ND-C2	pASK-1BA3	<i>E. coli</i>
pAN674	"	pOTP61	<i>B. subtilis</i>

These new plasmids combine production of extra PanB and PanD from a single vector and were predicted to produce increased levels of PanB relative to the *panB* expression vector (pAN636) present in PA668. The strategy to install the *P26 panBpanD* vectors in pantothenate production strains took advantage of genetic linkage between *bpr* and *panE1*. A derivative of PA824 was first constructed that is cured of the resident *panD* expression cassette by transforming the strain with chromosomal DNA isolated from PA930 (*panE1::cat*) and selecting for resistance to chloramphenicol. The resulting transformants were screened for sensitivity to tetracycline, and two Tet-sensitive isolates named PA715 were saved. This strain is the host strain for testing the *P26 panBpanD* vectors (see below). In order to restore the *P26 panE1* cassette in PA715, each vector was first transformed into a strain (PA328) that contains *P26 panE1* but does not contain a cassette integrated at the *bpr* locus. PA328 does contain the *P26 panBCD* locus although it is not engineered for overproduction of α -KIV. Transformants of PA328 resistant to tetracycline were obtained using the appropriate *NotI* restriction fragments from the two vectors and the resulting strains were named PA710 and PA714.

The next step was to transfer the cassettes into PA715 so they could be evaluated in the PA824 strain background. This was accomplished by isolating chromosomal DNA from strains PA710 and PA714 and using each of the two DNAs separately to transform PA715, with selection for resistance to tetracycline. Tetracycline-resistant transformants were screened for sensitivity to chloramphenicol; this identifies the desired transformants that have also acquired the *P26 panE1* gene from the donor DNA by linkage with the *P26 panBpanD* cassettes at the *bpr* locus. Chloramphenicol-sensitive isolates derived from transformations in which PA710 or PA714 chromosomal DNA was used as the donor were obtained. The isolates that produced the highest pantothenate titers in test tube culture assays were saved. These strains were named PA717 and PA721, respectively. Duplicate test tube cultures of the new strains, as well as PA824 and PA715, were grown in SVY + 10 g/L aspartate at 43°C for 48 hours and then assayed for pantothenate, HMBPA, and β -alanine. In addition, extracts from each of the strains were run on a SDS-PAGE gel. The results of the test tube culture assays are presented in Table 2.

Table 2. *Production of pantothenate by strains PA717 and PA721 grown in SVY plus 10 g/l aspartate.*

Strain	<i>panBD</i> cassette	[pan] (g/L)	[HMBPA] (g/L)	[β-ala] (g/L)
PA824	-	4.9	0.94	2.5
"		4.6	0.79	2.3
PA715	NONE	1.7	<0.1	0.5
"	"	1.7	<0.1	0.4
PA717-24	pAN670	4.8	0.34	1.3
"	"	4.9	0.40	1.3
PA721-35	pAN674	5.7	0.50	1.4
"	"	5.3	0.40	1.3
PA721-39	pAN674	4.1	0.38	2.0
"	"	4.6	0.40	2.2

5

As expected, each of the new strains produced more pantothenate and β-alanine than PA715. Two of the strains (PA717-24 and PA721-39) produced about as much pantothenate as PA824 while PA721-35 produced more pantothenate than PA824. All three of the new strains produced less HMBPA than PA824. The protein gel analysis showed that the three new strains produce more PanB than any of the control strains.

Strains PA717-24, PA721-35, and PA721-39 were also evaluated in shake flask cultures in a soy flour based medium. As shown in Table 3, these strains with the amplifiable *P26 panBpanD* cassette produced pantothenate and HMBPA at levels similar to the levels seen with PA668-2 and PA668-24 which both contain separate amplifiable *P26 panB* and *P26 panD* cassettes.

Table 3. Shake Flask Experiment 48 Hours

Medium	Strain	HMBPA (g/l)	PAN (g/l)
Soy flour + Glucose	PA668-2	1.2	6.8
	PA668-24	1.6	5.2
	PA717-24	2.0	5.9
	PA721-35	2.6	7.0
	PA721-39	2.5	8.6
Soy flour + Maltose	PA668-2	0.0	9.0
	PA668-24	0.4	10.4
	PA717-24	0.7	8.6
	PA721-35	1.0	9.2
	PA721-39	0.4	9.1

Conditions: 40ml medium / 200ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum (1.0 ml).

Soy Medium: 20 g/l Cargill 200/20 soy flour, 8 g/l (NH4)2SO4, 5g/l glutamate, 1x PSTE, 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2. 60 g/l glucose or maltose w/ 10 mM Mg and 1.4 mM Ca.

Average of duplicate flasks.

10

In addition to producing pantothenate (as well as other panto-compounds depicted in Figure 1 and described herein), it has been demonstrated that certain strains engineered for producing commercial quantities of desired panto-compound also produce a by-product identified as 3-(2-hydroxy-3-methyl-butylamino)-propionic acid (HMBPA) (also referred to herein as “β-alanine 2-(R)-hydroxyisovalerate”, “β-alanine 2-hydroxyisovalerate”, “β-alanyl-α-hydroxyisovalerate” and/or “fantothenate”). (The term “fantothenate” is also abbreviated as “fan” herein.)

15 HMBPA is the condensation product of [R]-α-hydroxyisovaleric acid (α-HIV) and β-alanine, catalyzed by the PanC enzyme. α-HIV is generated by reduction of α-KIV, a reaction that is catalyzed by the α-keto reductases PanE (e.g., PanE1 and/or PanE2) and/or IlvC. Thus it has been proposed that there exist at least two pathways in microorganisms that compete for α-KIV, the substrate for the biosynthetic enzyme PanB, namely the pantothenate biosynthetic pathway and the HMBPA biosynthetic

pathway. (A third and fourth pathway competing for α -KIV are those resulting in the production of valine or leucine from α -KIV, see e.g., Figure 1). At least the pantothenate biosynthetic pathway and the HMBPA biosynthetic pathway further produce competitive substrates for the enzyme PanC, namely α -HIV and pantoate.

5 Production of HMBPA can have significant effects on pantothenate production. For example, the HMBPA pathway can compete with the pantothenate pathway for precursors (α -KIV and β -alanine) and for some of the enzymes (PanC, PanD, PanE1, and/or IlvC). In addition, because the structure of HMBPA is similar to that of pantothenate, it may have the undesirable property of negatively regulating one or more
10 steps in the pantothenate pathway. Based on the identification of HMBPA, U.S. Provisional Patent Application Ser. No. 60/262,995 teaches that production of pantothenate can be improved or optimized by any means which favor use of substrates (α -KIV and β -alanine) and/or enzymes (PanC, PanD, PanE1, and/or IlvC) in pantothenate biosynthetic processes as compared to HMBPA biosynthetic processes.

15

Example II: Increasing Pantothenate Production by Increasing Serine Availability

At least one method for optimizing pantothenate production involves regulating the availability of serine in the microorganism cultures. In particular, it can
20 be demonstrated that increasing the availability of serine leads to increased pantothenate production (e.g., relative to HMBPA production), whereas decreasing the availability of serine leads to decreased pantothenate production relative to HMBPA production. This method is based on the understanding that the compound, methylenetetrahydrofolate (MTF), which is derived from serine, donates a hydroxymethyl group to α -KIV during
25 the pantothenate biosynthetic reaction to yield ketopantoate (see e.g., Figures 1 and 2). Thus, regulating serine levels is one means of effectively regulating ketopantoate levels and, in turn, regulating pantoate and/or pantothenate production in appropriately engineered microorganisms. To demonstrate this regulation, PA824 was grown in test tube cultures of SVY glucose plus 5 g/L β -alanine and \pm 5 g/L serine for 48 hours and
30 43°C.

Table 4: Production of pantothenate and HMBPA by PA824 with and without the addition of serine

serine added at 5 g/L	OD ₆₀₀	[pan] g/L	[HMBPA] g/L
-	16.3	4.9	0.84
-	14.0	4.5	0.80
+	13.1	6.4	0.56
+	12.9	6.0	0.62

5 As demonstrated by the data presented in Table 4, addition of serine increases the level of production of pantothenate (while conversely decreasing HMBPA production).

10 **Example III. Engineering bacterial cells with increased amounts of serine hydroxymethyl transferase, the *glyA* gene product.**

As an alternative to feeding serine, another method of increasing serine levels and/or serine utilization levels (and accordingly, methylenetetrahydrofolate levels) in order to regulate pantothenate production levels is to increase synthesis or the activity 15 of 3-phosphoglycerate dehydrogenase or of serine hydroxymethyl transferase (the *serA* and *glyA* gene products, respectively), thereby increasing serine and methylenetetrahydrofolate biosynthesis in appropriately engineered microorganisms.

Expression of the *glyA* gene was increased by transforming *B. subtilis* cells with an expression cassette containing the *B. subtilis* *glyA* gene cloned downstream 20 of a strong, constitutive promoter. To construct the expression cassette the primers RY417 and RY418 depicted in Table 5 were used to amplify the *glyA* gene by PCR from chromosomal DNA isolated from *B. subtilis* PY79.

Table 5: Primers used in the amplification of *B. subtilis* *glyA* and *serA*

RY405	CCCTCTAGAGGAGGGAGAAACATGTTCGAGTATTGGTC TCAGACAAAATG	SEQ ID NO:20
RY406	CCCGGATCCAATTATGGCAGATCAATGAGCTTCACAGAC ACAA	SEQ ID NO:21
RY417	GGATCTAGAGGAGGTGTAAACATGAAACATTACCTGCG CAAGACGAA	SEQ ID NO:22
RY418	CGGGGATCCCCCATCAACAATTACACACTTCTATTGATT CTAC	SEQ ID NO:23

RY417 contains the RBS2 synthetic ribosome binding site just downstream from an *XbaI* site. The amplified DNA was then cut with *XbaI* and *BamHI* and cloned between the *XbaI* and *BamHI* sites in vector pAN004 (Figure 5) to yield plasmid pAN396 (Figure 6; SEQ ID NO:24). The pAN004 vector contains the phage 5 SP01 P₂₆ promoter immediately upstream of the *XbaI* cloning site to drive expression of the cloned *glyA* gene. Just downstream of the expression cassette, pAN396 contains a *cat* gene that functions in *B. subtilis*. To transform *B. subtilis*, the *NotI* DNA fragment containing the *P26 glyA* cassette and *cat* gene was isolated from pAN396, self-ligated, and transformed into competent cells of *B. subtilis* PY79. Several chloramphenicol 10 resistant transformants were selected and named PA1007 and PA1008. Chromosomal DNA was isolated from each of these strains and used to transform competent cells of PA721B-39 and PA824 to yield strains PA1011 and PA1014, respectively. SDS polyacrylamide gel electrophoresis of cell extracts of selected isolates of PA1011 and PA1014 confirmed that these strains contained increased amounts of the *glyA* gene 15 product as compared to their parent strains PA721B-39 (described in Example I) and PA824 (described in International Public. No. WO 01/21772). To test the effect of increasing *glyA* expression on pantothenate production, PA1011 and PA1014 were grown in test tube cultures of SVY glucose plus 5 g/L β-alanine at 43°C for 48 hours. As shown by the data presented in Table 6, PA1014 produced more pantothenate (4.5 20 g/L) than its parent strain PA824 (3.2 g/L). Similarly, PA1011 produced on average more pantothenate (4.35 g/L) than its parent strain PA721B-39 (4.05 g/L).

Table 6. Production of pantothenate and HMBPA by PA1011 and PA1014 compared to PA721B-39 and PA824.

Strain	OD ₆₀₀	Pantothenate g/L	HMBPA g/L
PA1014 #1	14	4.5	0.27
PA1014 #2	15	4.5	0.31
PA824	16	3.1	0.31
PA824	15	3.3	0.28
PA1011 #1	17	4.5	0.24
PA1011 #2	12	4.2	0.27
PA721B-39	18	4.0	0.22
PA721B-39	16	4.1	0.25

**Example IV. Engineering bacterial cells with increased amounts of
3-phosphoglycerate dehydrogenase, the *serA* gene product.**

The product of the *serA* gene, 3-phosphoglycerate dehydrogenase, is the first committed enzyme in the pathway to serine biosynthesis (see Figure 2). Since 5 serine is one of the substrates for the synthesis of MTF, we engineered the overexpression of the *serA* gene to increase serine levels in the cell. In a manner similar to that described above for the *glyA* gene in Example III, expression of the *serA* gene was increased by transforming *B. subtilis* cells with an expression cassette containing the *B. subtilis* *serA* gene cloned downstream of a strong, constitutive promoter. To construct 10 the expression cassette the primers RY405 and RY406 depicted in Table 5 were used to amplify the *serA* gene by PCR from chromosomal DNA isolated from *B. subtilis* PY79. The amplified DNA was then cut with *Xba*I and *Bam*HI and cloned between the *Xba*I and *Bam*HI sites in vector pAN004 (Figure 5) to yield plasmid pAN393 (Figure 7; SEQ 15 ID NO:25). To transform *B. subtilis*, the *Not*I DNA fragment containing the *P26 serA* cassette and *cat* gene was isolated from pAN393, self-ligated, and transformed into competent cells of *B. subtilis* PY79. Several chloramphenicol resistant transformants were selected and named PA1004 and PA1005. Chromosomal DNA was isolated from each of these strains and used to transform competent cells of PA721B-39 and PA824 to yield strains PA1010 and PA1013, respectively. SDS polyacrylamide gel 20 electrophoresis of cell extracts of selected isolates of PA1010 and PA1013 confirmed that these strains contained increased amounts of the *serA* gene product as compared to their parent strains PA721B-39 and PA824.

To test the effect of increasing *serA* expression on pantothenate 25 production, PA1010 and PA1013 were grown in test tube cultures of SVY glucose plus 5 g/L β -alanine at 43°C for 48 hours. As shown by the data presented in Table 7, PA1010 produced on average more pantothenate (4.7 g/L) than its parent strain PA721B-39 (4.1 g/L). Similarly, PA1013 produced on average more pantothenate (4.1 g/L) than its parent strain PA824 (3.1 g/L).

30

Table 7. Production of pantothenate and HMBPA by PA1010 and PA1013 compared to PA721B-39 and PA824.

Strain	OD ₆₀₀	Pantothenate g/L	HMBPA g/L
PA1010 #3	16	4.8	0.23
PA1010 #5	15	4.5	0.26
PA1010 #6	22	4.7	0.24
PA721B-39	18	4.0	0.22
PA721B-39	16	4.1	0.25
PA1013 #2	14	3.3	0.25
PA1013 #4	14	4.2	0.28
PA1013 #5	16	5.5	0.37
PA1013 #8	13	3.6	0.24
PA824	17	3.0	0.27
PA824	16	3.1	0.29

Example V. Shake flask and fermentor experiments with strains with increased expression of *serA* and *glyA*.

Based on performance in test tubes, two strains with an amplifiable *serA* cassette and two strains with an amplifiable *glyA* cassette were selected, one each from two parents, PA824 and PA721B-39. The four strains were grown beside the parents in shake flasks (Table 8). In Soy flour MOPS Glucose (SMG) medium, all of the 4 strains produced more pantothenate than their parent strains. In Soy flour MOPS Maltose (SMM) medium one out of the four strains appeared superior to the parent strain.

The *serA* overexpressing strain and the *glyA* overexpressing strain from each parent were run simultaneously in 10-liter Chemap bench fermentors. The *glyA* overexpressing strain derived from PA824, PA1014-3, that had given the highest pantothenate titer in SMM, also performed the best in fermentors (Table 9). Strain PA1014-3 produced 71 g/l pantothenate in 36 hours in the culture supernatant and 86 g/l pantothenate in 48 hours in the culture supernatant compared to the parent PA824 which produced 41 g/l and 46 g/l pantothenate, respectively. The *serA* strain, PA1012-4, also produced significantly more pantothenate than the PA824 control in the culture supernatant, 52 g/l and 60 g/l at 36 and 48 hours, respectively. These results clearly demonstrate the effectiveness of increasing both *glyA* and *serA*.

The *serA* overexpressing and *glyA* overexpressing derivatives of PA721B-39 were clearly improved over their parent strain as well. Both produced about 80 g/l pantothenate (82 g/l and 79 g/l, respectively) in the culture supernatants in 48 hours. The effect of the increased PanB levels in the PA721B-39 derivatives versus the PA824 derivatives manifests itself in the reduction of HMBPA. PA721B-39 and its derivatives produce less HMBPA after 48 hours than PA824 or even PA668-24. Increasing GlyA also appears to lower the flow of carbon to HMBPA.

10 *Table 8. Shake flask evaluation of pantothenate production strains overexpressing serA or glyA .*

Carbon source	Strain	Added cassette	HMBPA (g/l)	Pantothenate (g/l)
Glucose	PA824		3.5	4.0
	PA1012-4	<i>serA</i>	3.0	4.6
	PA1014-3	<i>gly A</i>	2.5	4.7
	PA721B-39		0.9	5.0
	PA1010-6	<i>serA</i>	1.9	9.6
	PA1011-2	<i>gly A</i>	1.7	10.0
Maltose	PA824		1.2	10.4
	PA1012-4	<i>serA</i>	0.8	9.8
	PA1014-3	<i>gly A</i>	1.1	16.1
	PA721B-39		0.6	11.6
	PA1010-6	<i>serA</i>	0.5	10.2
	PA1011-2	<i>gly A</i>	0	10.3

All data are the average of duplicate shake flasks after 48 hours.

15 Conditions: 40ml medium / 200ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum and 43°C.

Medium: 20 g/l Cargill 200/20 soy flour, 1 x PSTE, 8 g/l (NH4)2SO4 and 5g/l glutamate.
Buffer: 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2.

20 Carbon Source (Sterilized separately as 20 x stock): 60 g/l glucose or maltose w/ 10 mM Mg and 1.4 mM Ca.

Table 9. 10 liter fermentor evaluations of pantothenate production strains overexpressing *serA* or *glyA*.

run	Strain	Parent	Added cassette	HMBPA (g/l)		Pantothenate (g/l)	
				36 hrs	48 hrs	36 hrs	48 hrs
P285	PA824			18	25	41	46
P284	PA1012-4	PA824	<i>serA</i>	20	21	52	60
P286	PA1014-3	PA824	<i>glyA</i>	14	16	71	86
P259	PA721B-39			4	5	34	42
P287	PA1010-6	PA721B-39	<i>serA</i>	4	5	65	82
P289	PA1011-2	PA721B-39	<i>glyA</i>	2	3	56	79
P275	PA668-24	PA824		3	9	55	72

5

The medium used is PFM-222. It is the same as medium PFM-155 described in U.S. Ser. No. 60/262,995 (filed January 19, 2001) except for the following changes: (1) In the Batch Material: There is no Amberex 1003. Cargill 200/20 (soy flour) 40 g/L has been changed to Cargill 20-80 (soy grits) 50 g/L, MgSO₄·7H₂O is replaced with MgCl₂·7H₂O, 1 g/L, and SM-1000X is replaced with PSTE-1000X (PSTE-1000X = MnCl₂·4H₂O, 2.0 g/L; ZnSO₄·7H₂O, 1.5 g/L; CoCl₂·6H₂O, 2.0 g/L; CuSO₄·5H₂O, 0.25 g/L; Na₂MoO₄·2H₂O, 0.75 g/L). In the Feed Material: SM-1000X is replaced with PSTE-1000X

10

Increasing pantothenate production can also be achieved by combining overexpression of *serA* and *glyA* in a single strain, and/or by introducing a mutation that 15 leads to feedback resistant *serA* or *glyA*, or both.

Example VI. Increasing the expression of the *glyA* gene by mutating the *purR* gene.

As described in Examples III and V, expression of the *glyA* gene can be increased by adding one or more copies of a cassette in which the *glyA* gene is driven by a strong, constitutive promoter. An alternative method to increase *glyA* expression is to alter its regulation. Literature describing a *glyA*::*lacZ* fusion suggests that the *glyA* promoter is of moderate strength under normal conditions (about 400 Miller Units), but that this promoter is capable of being induced to relatively high levels (1,800 Miller units) if its negative regulator, the *purR* gene, is deleted (Saxild *et al.* (2001) *J. Bacteriol.* 183:6175-6183). Therefore, experiments were preformed to determine if *glyA*

expression, and consequently pantothenate production, could be increased by deleting *purR* from a pantothenate production strain.

The *B. subtilis* *purR* gene was amplified from PY79 chromosomal DNA by PCR, and the resulting fragment was cloned into PvuII cleaved pGEM5-Zf(+) vector 5 DNA to give plasmid pAN835F (SEQ ID NO:26, Figure 8). This step eliminated the PvuII sites at both ends of the insert, leaving a unique PvuII site in the middle of the *purR* open reading frame. Next, a blunt PCR DNA fragment containing the Gram positive kanamycin resistance gene from pAN363F (SEQ ID NO:27) was ligated into this unique PvuII site of pAN835F to give pAN838F (SEQ ID NO:28, Figure 9).

10 pAN838F was then transformed into PY79, PA668-24, and PA824, selecting for kanamycin resistance at 10 mg/l to give new sets of strains named PA1059, PA1060, and PA1061, respectively. It was shown by PCR that all new isolates contained the disrupted *purR::kan* allele that was expected from a double crossover event. Several isolates of PA1060 and PA1061 were tested for pantothenate production 15 in test tube cultures grown in SVY glucose plus β-alanine (Table 9). The best isolates derived from PA668-24, PA1060-2 and PA1060-4, gave an improvement from 3.0 g/l pantothenate to 5.3 to 5.1 g/l, respectively, which is an increase of 75%. Likewise, the best isolates derived from PA824, PA1061-1 and PA1061-2 gave an increase from about 3.1 g/l to 5.4 g/l, also a 75% gain. These results suggest that the *glyA* gene is 20 substantially induced in these new strains by disruption of the *purR* gene. Alternatively, the improvements in pantothenate production in PA1060 and PA1061 may be due to more complex pleiotropic effects. In either case, deregulation of the *purR* regulon has a positive effect on pantothenate production.

In other embodiments, the *purR* disruption can be installed in other 25 pantothenate production strains, for example those that have an integrated *P26serA* allele or more than one copy of the *P26panBCD* operon. The *purR* gene can also be used as a site for addition of desired expression cassettes, such as *P26panB*. One can also use resistance to the guanine analogs, such as 8-azaguanine, as a selection for a *purR* mutation.

Table 10. Production of pantothenate and farnothenate by derivatives of PA824 and PA668-24 containing disrupted purR, in test tube cultures grown in S/VY glucose plus 5 g/l β-alanine.

Strain	inoculum*	parent	new feature	OD ₆₀₀	[fan] g/l	[pan] g/l
PA668-24	cam 5, tet 7.5	PA824	-	9	b.d.	3.0
"	"	"	-	12	b.d.	3.0
PA1060-1	cam 5, tet 7.5	PA668-24	<i>purR::kan</i>	14	0.14	4.5
PA1060-2	"	"	"	12	b.d.	5.3
PA1060-3	"	"	"	12	b.d.	4.5
PA1060-4	"	"	"	16	0.11	5.1
PA824	tet 30	PA377	-	9	0.25	3.2
"	"	"	-	11	0.22	3.0
PA1061-1	tet 15	PA824	<i>purR::kan</i>	13	0.45	5.4
PA1061-3	"	"	"	14	0.39	5.4
PA1061-4	"	"	"	11	0.40	4.7

b.d. = below detection

* Concentration of antibiotics in the petri plate from which the inoculum colony was taken.

Example VII. Overexpression of the *serA* gene from a non-amplifiable cassette.

This Example describes another method to increase serine production, in which a two step procedure deposits a strong, constitutive promoter (*P₂₆*) in front of the chromosomal *serA* gene. Two plasmids were constructed, each containing about 700 base pairs of DNA sequence from the region immediately upstream of the native *serA* gene. The first plasmid, pAN821, also contains the 3' half of the *serA* coding region, and in between the two aforementioned sequences, a kanamycin resistance gene (SEQ ID NO:30, Figure 10). When transformed into *B. subtilis*, selecting for kanamycin resistance, pAN821 will give a disruption of the *serA* gene, leading to serine auxotrophy. This creates a genetic sequence termed the *ΔserA::kan* allele.

The second plasmid, designed to introduce the *P₂₆ serA* structure, was constructed by inserting the *serA* upstream sequence at the 5' end of the *P₂₆* promoter in pAN395. The resulting plasmid, pAN824, is shown in Figure 11 (SEQ ID NO:31). The plasmid pAN395 is similar to pAN393 described in Example IV. The open reading frame of the *serA* gene was synthesized by PCR using *B. subtilis* PY79 DNA as the template. The upstream primer contains an *Xba*I site and a moderately strong synthetic ribosome binding site, RBS2. The downstream primer contains a *Bam*HI site. This *serA* open reading frame was used to replace the *panBCD* genes in the medium copy plasmid, pAN006, to give pAN395 (SEQ ID NO:29, Figure 12). This plasmid contains the *serA* gene expressed from the *P₂₆* promoter and the RBS2 ribosome binding site.

The *ΔserA::kan* allele from pAN821 was introduced into strain PA824 to give PA1026. As expected, PA1026 did not grow on minimal medium. In the second step, the *P₂₆ serA* cassette from plasmid pAN824 was introduced into PA1026, selecting for serine prototrophy, to give strain PA1028. Several PA1028 isolates were confirmed to have the expected chromosomal structure (*P₂₆ serA*) by diagnostic PCR. These isolates were then tested for pantothenate production in test tube cultures grown for 48 hours in SVY plus 5 g/l β-alanine (Table 11). The PA1028 isolates (derived from PA824) gave increases from 10% to 25% in pantothenate production. As shown in Table 12, in shake flask experiments, PA824 produced about 7 g/l pantothenate, whereas PA1028 produced 11 g/l.

Example VIII. Construction of pantothenate producing strains that contain both an integrated non-amplifiable P_{26} *serA* cassette and an amplifiable P_{26} *glyA* cassette.

5 Since a non-amplifiable P_{26} *serA* cassette integrated at *serA* led to higher pantothenate synthesis (see, e.g., Table 12), and since a chloramphenicol amplifiable P_{26} *glyA* cassette at *glyA* led to much higher pantothenate synthesis (see, e.g., PA1014-3, Table 8), it was proposed that a combination of the two might be synergistic. Strain PA1028-4, which is the derivative of PA824 that contains the non-amplifiable P_{26} *serA* cassette integrated at *serA*, was transformed to chloramphenicol resistance at 5 mg/l using chromosomal DNA from PA1014-3, to give a set of strains named PA1038, which now contain the chloramphenicol amplifiable P_{26} *glyA* cassette. PA1038 isolates were tested for pantothenate production using standard test tube cultures grown in SVY plus β -alanine (Table 13). As expected, PA1038 showed a dramatic increase in pantothenate 10 production from about 4.2 g/l by PA824 to 6.6 to 7.5 g/l by the PA1038 set. Isolates PA1038-3 and PA1038-12 were further tested in shake flasks as shown in Table 12. Both produced an average of 13.6 g/l pantothenate, as compared to the 7.4 g/l 15 pantothenate produced by PA824.

20 **Table 11. Production of pantothenate and fantothenate by derivatives of PA824 that contain a single copy of P_{26} *serA* at the *serA* locus, in 48 hour test tube cultures grown in SVY plus 5 g/l β -alanine.**

Strain	parent	OD ₆₀₀	[fan] g/l	[pan] g/l
PA824		17	0.44	4.0
PA824		15	0.45	4.0
PA1028-1	PA824	13	0.46	4.4
PA1028-2	"	18	0.49	4.9
PA1028-3	"	15	0.44	4.4
PA1028-4	"	13	0.43	4.5
PA1028-5	"	14	0.45	4.4
PA1028-6	"	11	0.43	4.8
PA1028-8	"	15	0.51	5.0

25

b.d. = below detection

Table 12. Shake flask evaluation of pantothenate production strains overexpressing serA and/or glyA.

Strain	Parent	glyA cassette	serA cassette	Fantothenate (g/l)	Pantothenate (g/l)
PA824				0.6	7.4
PA1014-3	PA824	N x P ₂₆ glyA		0.7	12.0
PA1028-4	PA824		P ₂₆ serA @ serA	0.8	11.1
PA1038-3	PA1028-4	N x P ₂₆ glyA	P ₂₆ serA @ serA	0.5	13.6
PA1038-12	PA1028-4	N x P ₂₆ glyA	P ₂₆ serA @ serA	0.6	13.6

All data are the average of duplicate shake flasks after 48 hours.

Conditions: 40 ml medium / 200 ml baffled shake flask, 4X Bioshield covers, 300 rpm, 2.5% inoculum and 43°C.

Inoculum: SVY base w/maltose 24 hours at 43°C.

Medium: 20 g/l Cargill 200/20 soy flour, 8 g/l (NH₄)₂SO₄, 5 g/l glutamate and 1x FSTE.

Buffer: 0.1M phosphate pH 7.2 and 0.3M MOPS pH 7.2.

Carbon Source (Sterilized separately as 20X stock): 30 g/l maltose, 5 mM MgCl₂ and 0.7 mM CaCl₂.

Table 13. Pantothenate production by PA1038, a derivative of PA824 that contains a non-amplifiable P_{26} serA cassette at serA and an amplifiable P_{26} glyA cassette at glyA.

5

Strain	Inoculum Medium	OD ₆₀₀	[Fan] g/L	[Pan] g/L
PA824	tet 15	16	0.56	4.4
PA824	"	14	0.59	4.3
PA824	tet 30	12	0.57	4.3
PA824	"	14	0.58	4.2
PA1038-3	cam 5, tet 15	16	0.47	7.2
PA1038-4	"	14	0.49	7.0
PA1038-5	"	15	0.52	7.0
PA1038-6	"	15	0.51	7.2
PA1038-9	"	14	0.56	7.2
PA1038-11	"	13	0.49	6.6
PA1038-12	"	16	0.58	7.5

Test tube cultures were grown with SVY glucose plus 5 g/l β -alanine at 43°C for 48 hours.

10

Example IX. Increasing the production of MTF by altering the glycine cleavage pathway.

As demonstrated with the above examples, increasing MTF production in bacteria increases the production of pantothenate in strains that have been engineered to produce more pantothenate by manipulation of the *panBCD* and/or *panE* genes. It has been demonstrated that pantothenate production can be increased by increasing the expression of the *glyA* or the *serA* gene. Stronger promoters or ribosome binding sites can be used to increase *glyA* or *serA* expression as demonstrated in Examples III through V and VII through VIII. Alternatively, the expression of the *glyA* gene can be deregulated in *Bacillus* by disrupting the *purR* repressor gene as illustrated in Example VI.

Another method to increase MTF production is to enhance the expression of enzymes of the glycine cleavage pathway. For example, enzymes encoded by the *gcvT*, *gcvPA*, *gcvPB*, *gcvH*, and *pdhD* genes catalyze the breakdown of glycine to MTF, CO₂, and NH₃. A strong, constitutive promoter, such as the SP01 phage *P₂₆* promoter described previously, can be cloned in front of the *gcvT-gcvPA-gcvPB* operon or in front of the *gcvH* or *pdhD* gene to enhance their expression. In addition to the above

mentioned approaches, additional glycine, which is inexpensive, can be added to the medium to further enhance MTF production by any strain engineered as described herein.

5

Equivalents Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

10

What is claimed:

1. A process for the enhanced production of pantothenate, comprising culturing a microorganism having a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, under conditions such that pantothenate production is enhanced.
2. A process for the enhanced production of pantothenate, comprising culturing a microorganism having
 - (i) a deregulated pantothenate biosynthetic pathway, and
 - (ii) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway,under conditions such that pantothenate production is enhanced.
3. The process of claim 2, wherein said microorganism has at least two pantothenate biosynthetic enzymes deregulated.
4. The process of claim 2, wherein said microorganism has at least three pantothenate biosynthetic enzymes deregulated.
5. The process of claim 2, wherein said microorganism has at least four pantothenate biosynthetic enzymes deregulated.
6. The process of claim 5, wherein said microorganism has a deregulated ketopantoate hydroxymethyltransferase, a deregualted ketopantoate reductase, a deregulated pantothenate synthetase and a deregulated aspartate- α -decarboxylase.
7. The process of any one of claims 1 to 6, wherein said microorganism further has a deregulated isoleucine-valine (*ilv*) biosynthetic pathway.
8. The process of claim 7, wherein said microorganism has at least two isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.
9. The process of claim 7, wherein said microorganism has at least three isoleucine-valine (*ilv*) biosynthetic enzymes deregulated.

10. The process of claim 9, wherein said microorganism has a deregulated acetohydroxyacid acid synthetase, a deregulated acetohydroxyacid isomeroreductase, and a deregulated dihydroxyacid dehydratase.

5 11. The process of any one of claims 1 to 10, wherein the microorganism has at least one MTF biosynthetic enzyme deregulated.

12. The process of claim 11, wherein the microorganism has a deregulated *glyA* gene.

10

13. The process of claim 11, wherein the microorganism has a deregulated *serA* gene.

15

14. The process of claim 11, wherein the microorganism has a deregulated *glyA* gene and a deregulated *serA* gene.

15. The process of claim 12 or 14, wherein the microorganism has a mutated, deleted or disrupted *purR* gene.

20

16. A process for the enhanced production pantothenate, comprising culturing a microorganism having a deregualted pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway deregulated, such that production of pantothenate is enhanced.

25

17. A process for the production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, such that at least 50 g/L pantothenate is produced after 36 hours of culturing the microorganism.

30 18. The process of claim 17, comprising culturing the microorganism such that at least 60 g/L pantothenate is produced after 36 hours of culturing the microorganism.

35

19. The process of claim 17, comprising culturing the microorganism such that at least 70 g/L pantothenate is produced after 36 hours of culturing the microorganism.

20. A process for the production pantothenate, comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated isoleucine-valine (*ilv*) biosynthetic pathway, and a deregulated 5 methylenetetrahydrofolate (MTF) biosynthetic pathway deregulated, such that at least 60 g/L pantothenate is produced after 48 hours of culturing the microorganism.

21. The process of claim 20, comprising culturing the microorganism such that at least 70 g/L pantothenate is produced after 48 hours of culturing the 10 microorganism.

22. The process of claim 20, comprising culturing the microorganism such that at least 80 g/L pantothenate is produced after 48 hours of culturing the microorganism.

15

23. The process of any one of the preceding claims, wherein pantothenate production is further enhanced by regulating pantothenate kinase activity.

20

24. The process of claim 23, wherein pantothenate kinase activity is decreased.

25. The process of claim 24, wherein CoA is deleted and CoaX is downregulated.

25

26. The process of claim 24, wherein CoaX is deleted and CoA is downregulated.

30

27. The process of claim 24, wherein CoaX and CoA are downregulated.

28. The process of any one of the above claims, wherein said microorganism is cultured under conditions of excess serine.

35

29. A process for producing pantothenate comprising culturing a microorganism having a deregulated pantothenate biosynthetic pathway under conditions of excess serine, such that pantothenate is produced.

30. The process of any one of the above claims, wherein said microorganism has the pantothenate biosynthetic pathway deregulated such that pantothenate production is independent of β -alanine feed.

5 31. The process of any one of the above claims wherein the microorganism is a Gram positive microorganism.

32. The process of any one of the above claims wherein the microorganism belongs to the genus *Bacillus*.

10

33. The process of any one of the above claims, wherein the microorganism is *Bacillus subtilis*.

15

34. A product synthesized according to the process of any one of the above claims.

35. A composition comprising pantothenate produced according to the process of any one of the above claims.

20

36. A recombinant microorganism for the enhanced production of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, and a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway.

25

37. A recombinant microorganism for the enhanced production of pantothenate, said microorganism having a deregulated pantothenate biosynthetic pathway, a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway, and a deregulated isoleucine-valine (*ilv*) pathway.

30

38. The microorganism of claim 36 or 37, further having reduced pantothenate kinase activity.

39. The microorganism of any one of claims 36-38 which is a Gram positive microorganism.

35

40. The microorganism of any one of claims 36-38 belonging to the genus *Bacillus*.

41. The microorganism of any one of claims 36-38 which is *Bacillus subtilis*.

42. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) at least one deregulated isoleucine-valine (*ilv*) biosynthetic enzyme-encoding gene;

under conditions such that at least 30 g/l pantothenate is produced after 36 hours of culturing the microorganism.

43. The process of claim 42, wherein said microorganism further has a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway and said microorganism is cultured under conditions such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

44. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene; and
- (b) a deregulated *panD* gene;

under conditions of excess serine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

45. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated methylenetetrahydrofolate (MTF) biosynthetic pathway;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

46. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated *glyA* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

47. A process for producing pantothenate comprising culturing a
5 recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a mutated, deleted or disrupted *purR* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is
10 produced after 36 hours of culturing the microorganism.

48. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene; and
- (c) a deregulated *serA* gene;

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

20 49. A process for producing pantothenate comprising culturing a recombinant microorganism having:

- (a) a deregulated *panB* gene;
- (b) a deregulated *panD* gene;
- (c) a deregulated *serA* gene;
- (d) a deregulated *glyA* gene; and

under conditions of excess valine, such that at least 50 g/l pantothenate is produced after 36 hours of culturing the microorganism.

FIG.




FIG. 2




FIG. 3





FIG. 4




FIG. 5




FIG. 6




FIG. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11





Fig. 12



SEQUENCE LISTING

<110> OmniGene BioProducts, Inc. et al.

<120> MICROORGANISMS AND PROCESSES FOR ENHANCED PRODUCTION OF PANTOTHENATE

<130> BGI-154PC

<160> 31

<170> PatentIn Ver. 2.0

<210> 1

<211> 194

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter sequence

<220>

<221> -35_signal

<222> (136)..(141)

<220>

<221> -10_signal

<222> (159)..(164)

<400> 1

gctattgacg acagctatgg ttcaactgtcc accaacccaaa actgtgctca gtaccgc 60
tatttctccc ttgagggta caaaagggtt tccctagaag agatccacgc tgtgtaaaaa 120
ttttacaaaa aggtattgac tttccctaca gggtgtgtaa taatttaattt acaggcgggg 180
gcaaccccgctgt 194

<210> 2

<211> 163

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:promoter sequence

<220>

<221> -35_signal

<222> (113)..(118)

<220>

<221> -10_signal

<222> (136)..(141)

<400> 2

gcctacccatg cttccaagaa agatatccta acagcacaag agcggaaaga tgtttg 60
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120

atctacaagg tgtggtataa taatcttaac aacagcagga cgc 163

<210> 3
<211> 127
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:promoter sequence

<220>
<221> -35_signal
<222> (34)..(39)

<220>
<221> -10_signal
<222> (58)..(63)

<220>
<221> -35_signal
<222> (75)..(80)

<220>
<221> -10_signal
<222> (98)..(103)

<400> 3
gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60
aatttaaatt ttatttgaca aaaatggct cgtgttgtac aataaatgta gtgaggtgga 120
tgcaatg 127

<210> 4
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 4
taaacatgag gaggagaaaa catg 24

<210> 5
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 5
attcgagaaa tggagagaat ataatatg 28

<210> 6

<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<400> 6
agaaaaggagg tga

13

<210> 7
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 17, 18, 19, 20
<223> n = a, t, c, or g

<400> 7
ttaagaaagg aggtgannnn atg

23

<210> 8
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 16, 17, 18, 19, 20
<223> n = a, c, t, or g

<400> 8
ttagaaagga ggtgannnnn atg

23

<210> 9
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome
binding site

<220>
<221> misc_feature
<222> 14, 15, 16, 17, 18, 19, 20
<223> n = a, c, t, or g

<400> 9
agaaaaggagg tgannnnnnn atg 23

<210> 10
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<220>
<221> misc_feature
<222> 14, 15, 16, 17, 18, 19
<223> n = a, c, t, or g

<400> 10
agaaaaggagg tgannnnnna tg 22

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 11
ccctctagaa ggaggagaaa acatg 25

<210> 12
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 12
ccctctagag gaggagaaaa catg 24

<210> 13
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 13
tttagaaagga ggatttaaat atg 23

<210> 14
<211> 23
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 14
ttagaaagga ggtttaatta atg 23

<210> 15
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 15
ttagaaagga ggtgatttaa atg 23

<210> 16
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 16
ttagaaagga ggtgtttaaa atg 23

<210> 17
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 17
attcgagaaa ggaggtgaat ataataatg 28

<210> 18
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 18
attcgagaaa ggaggtgaat aataatg 27

<210> 19
<211> 28

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:ribosome binding site

<400> 19
attcgttagaa aggaggtgaa ttaatatg 28

<210> 20
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:5' PCR primer
<223> for serA gene

<400> 20
ccctcttagag gaggagaaaa catgtttcga gtattggtct cagacaaaaat g 51

<210> 21
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:3' PCR primer
<223> for serA gene

<400> 21
cccggtatcca attatggcag atcaatgagc ttcacagaca caa 43

<210> 22
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:5' PCR primer
<223> for glyA gene

<400> 22
ggatcttagag gaggtgtaaa catgaaacat ttacctgcgc aagacgaa 48

<210> 23
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:3' PCR primer
<223> for glyA gene

<400> 23
cggggatccc ccatcaacaa ttacacactt ctattgattc tac 43

<210> 24

<211> 7926

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:serA overexpression

<223> plasmid

<400> 24

gaattttgcg gccgcttcga aagctgtaat ataaaaaccc tcttcaacta acggggcagg 60
ttagtgacat tagaaaaccc actgtaaaaa gtacagtccg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaaacaat cctgcatgt 180
aaccatcaca aacagaatga tgtacctgt aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttcctgt gtaataatgg gtagaaaggta attactatta ttatttgat 300
ttaagttaaa cccagtaaat gaagtccatg gaataataga aagagaaaaa gcattttcag 360
gtataggtgt tttggaaac aatttccccg aaccattata ttctctaca tcagaaaggt 420
ataaaatcata aaactctttg aagtcatctt ttacaggagt ccaaatacca gagaatgttt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540
cgtcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc agggtaaaaat ttatatcctt ctgttttat gtttcggat aaaacactaa 660
tatcaatttc tgggttata ctaaaagtcg tttgttggtt caaataatga taaaatatct 720
ctttctctt ccaattgtct aaatcaattt tattaaagtt catttgat 780
tttttatcta aagtgaattt aggaggctt ctgtctgt ttcttcatta gaatcaatcc 840
tttttaaaa gtcaatattt ctgtaacata aatataattt tttttat 900
ccaattttcg tttgttgaac taatgggtgc ttttagtgaa gaataaaagac cacataaaa 960
aatgtggct tttgtgttt tttaaaggat ttgagcgtag cgaaaaatcc ttttcttct 1020
tatcttgata ataagggtaa ctattgaatt cggtaccaag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgtttaa ttgtatgcct ggcagttat ggccggcgtc 1140
ctgcccgc当地 ccctccgggc cggtgtttcg caacgttcaa atccgttccc ggccgat 1200
tcctactcg gagagcgttcc accgacaaaac aacagataaa acgaaaggcc cagtcttcg 1260
actgagcctt tcgttttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttactt tctgaggctcg gcatgggtc aggtgggacc 1380
accgcgtac tgccgcccagg caaattctgt tttatcagac cgcttctgcg ttctgat 1440
atctgtatca ggctgaaaat cttctctcat ccgcggaaaac aggtatccat tatggcagat 1500
caatgagctt cacagacaca atatcaggga catttggtag ttcttcaca attttatctt 1560
ccagatgtct gtcaaaggaa agcatcatga tggcttctcc gccttttcc ttacggccaa 1620
cctgcatagt tgcaatgtta atatcattat ctccgagaat acgttctact cggccgat 1680
cacctgttgt atcttgatgc tggatataca ccaagtgacc agtccgat 1740
taaatccatt gatctcgaca attcttctc cggaaatgagg aatatacgta gccgttacag 1800
taaagggtct ggggtcttctt gtcactttt cgtctatgcgatgtca ttatcgat 1860
aagaggaaat ttttctactg aagctaattgc cgcgttctt tgcgacacccc cggcattga 1920
cctcattaac agtagagtct acgcgcgggtt ttaaaaagcc tgacagaagg gctttgtaa 1980
tgaacgatgt ttcaagttt gcaattgtgc ttccatattt aatggcaaca tcctgtact 2040
gttcttcat gcactgtat acaaggctgc caattttcc tgcattttga tggtaaggct 2100
taatttttagc aaattcatct tttgtcatgg caggcagggtt gatagctgac atgacaggca 2160
ggccctttgc gaactgcaga acttcttctg acacttggc ggcgacattt agctgtgctt 2220
ctttcggtga tgctcccaag tgaggagtgg caatgactaa tggatgatca acaagttgt 2280
tgtcaactgg cgggtcgact tcgaaaacgt caagcgctgc tcccgcaaca tgccgtttt 2340
ccaaagcttc gagaagtgtct gcttcatcgta taattccgccc tgcgcacag ttaattaagc 2400
gaacgcctt tttcggtttt gcaatcggtt ttatatttca taagcctttt gtttctttt 2460
ttaaaggcgt gtgaacggta atgatatccg cacttcaag cacttcttca aatgtacggc 2520
tgtttacgcc gattttttc gctttttctt cggtaagaa aggtatccaa acgtgcacag 2580
tcataccgaa cgctcctcgaa cgctgtgcaaa ttctacttcc gattcggcctt aatcctacaa 2640
taccaagcgt tttccatcaa agctctgaac cgacataagc tggcgggttc cactctctgg 2700
atttcaactga gatatttagcc tgccgaatgt gtcttattaa agaagagatc attgcaat 2760
tatgctcagc tgcgaaatg gtgttgcgt tcggagcatt gatcacgtt accccgtgtt 2820
tcgttagcctc atcaatatcg atattatcg caccgacacc ggcttcccg acaatttttta 2880
aagaagtcat ttgttggaaa aggtctctg ttactttgt cgcgttccgc accaaaagag 2940
catcaaaaatgtatca tcttcgtat ctgtacgtt ttttgaacg atttcaataaa 3000

agtctgattc aataagtggc tgtaaacgt cggtgcgtat tttgtctgag accaatactc 3060
gaaacatgtt ttctcccttc ctagagcgcc ctgtgttgt taagattatt ataccacacc 3120
tttgatgataa agtcaacaac tttttgcaaa atttttcagg aatttttagca gaggtgttc 3180
tggatgtaga acaaaaacate ttcccgtct tttgtgttga ggatatctt cttggaaagct 3240
aggttaggcct cgagttatgg cagttggta aaaggaaaca aaaagaccgt tttcacaccaa 3300
aacggcttt ttcgatttct ttttacagtc acagccactt ttgcaaaaaac cggacagctt 3360
catgccttat aactgctgtt tcggcgaca agcttcgca agcggccgca aaatttcaactg 3420
gcgcgtgtt tacaacgtcg tgactggaa aaccctggcg ttacccaact taatcgccct 3480
gcagcacatc ccccttcgc cagctggcgta aatagcgaag aggccccgac cgatcgccct 3540
tcccaacagt tgccgagcct gaatggcgaa tggccctgtc tgccgttatt ttccttacg 3600
catctgtgcg gtatttcaca ccgcataatgg tgcactctca gtacaatctg ctctgatgcc 3660
gcatagttaa gccaggccccg acaccgcgc acaccgcgt actatgcgtt taaaccgtt 3720
tgtgaaaaaa tttttaaaat aaaaaagggg acctctagg tcccccaatta attagtaata 3780
taatctatta aaggtcattc aaaaggtcat ccaccggatc agcttagtaa agccctcgct 3840
agatttiata gggatgttg cgattactc gccaactatt gegataacaa gaaaaagcca 3900
gccttcatg atatatctcc caatttgcgtt agggcttatt atgcacgctt aaaaataata 3960
aaagcagact tgacctgata gtttggctgt gagcaattat gtgccttagt catctaacgc 4020
ttgagttaa cgcgcgcgcg aagcggcgca ggcttgaacg aattttaga cattatttgc 4080
cgactacctt ggtgatctcg ctttcacgt agtggacaaa ttctccaac ttagtctgcgc 4140
gcgaggccaa gcgatcttct tcttgccaa gataaggctg tctagctca agttagacgg 4200
gctgatactg ggcggcagg cgctccattt cccagtcgac agcgcacatcc ttccggcgcga 4260
ttttgcgggt tactgctgtc taccaatgc gggacaacgt aagcactaca ttccgctcat 4320
cgccagccca gtcgggcggc gagttccata gcgtaaagg ttcatttagc gcctcaaata 4380
gatctgttc aggaaccggc tcaaagagtt cctccgcgc tggacctacc aaggcaacgc 4440
tatgttctct tgctttgtc agcaagatag ccagatcaat gtcgatcg tctggctcga 4500
agataacctgc aagaatgtca ttgcgtgccc atttccaaa ttgcagttcg cgcttagctg 4560
gataacgcca cggaatgtat tcgtcgca caacaatgtt gacttctaca ggcggagaa 4620
tctcgcttc tccaggggaa gccgaagttt caaaagggtc gttgatcaaa gctccgcgc 4680
ttgttccatc aagccttacg gtcaccgtaa ccagcaaat aatatcaactg tttggcttca 4740
ggccgcacatc cactgcggag ccgtacaaat gtacggccag caacgtcggt tcgagatggc 4800
gctcgatgac gccaactacc tctgatagtt gagtcgatac ttccgcpac accgcttccc 4860
tcatgatgtt taactttgtt ttagggcgac tgccctgtc cgtaacatcg ttgctgtcc 4920
ataacatcaa acatcgaccc acggcgtaac gcgcttgcgtt cttggatgcc cgaggcatag 4980
actgtacccc aaaaaaacag tcataacaag ccatgaaaac cgccactcg tggcttccatc 5040
cgctcggtt ggtcaagggtt ctggaccagt tgcgtgagcg catacgctac ttgcattaca 5100
gcttacgaac cgaacaggct tatgtccact gggctcgatc ttccatccgt ttccacgggt 5160
tgcgtcacc ggcacaccc ggcacaccc ggcacaccc ggcacaccc tggctggcg 5220
acgagcgca ggttccgtc tccacgcata gtcaggcatt ggcggccttgc tggcttctct 5280
acggcaaggt gctgtgcacg gatctccct gccttcagg gatcggaaaga cctccggcgt 5340
cgccgcgtt gccgggtgtc ctgaccggg atgaagtgtt tcgcattccctt ggtttctgg 5400
aaggcgagca tcgtttgttc gcccacgtt tttatggac gggcatgcgg atcagtggagg 5460
gtttgcaact gccccgtcaag gatctggatt tcgatcacgg cacgatcatc gtgcgggagg 5520
gcaagggtctc caaggatcg gcttgcgtt taccggagag ctggcaccc acctcgccgc 5580
agcaggggaa ttgatccgtt ggtacaccc ttgatgacc ttaatagat tataattacta 5640
attaatttgg gaccctagag gtcacccctt ttatttaaa aatttttca caaaacgtt 5700
tacaagata acgggttttgc tggccgcaaa acgggtcttt ctgggttgc tagtttttta 5760
tcagaatcgc agatccgct tcagggttgc cggctgaaag cgctatttct tccagaattt 5820
ccatgatttt ttccccacgg gaggcgatc tggctccgtt gttgtcgca gctttgattt 5880
gataagcagc atcgccgtt tcaggctgtc tatgtgtgac tggtagctg taacaagggtt 5940
tctcagggtt tcaatttcat gttctagttt ctttgcattt ctgggttgc tggcttctatt 6000
aggtgttaca tgctgttcat ctgttacatt gtcgtatgt tcatgtgaa cagctttaaa 6060
tgcaccaaaa actcgtaaaa gctgtatgtt atctatctt tttacaccgt tttcatctgt 6120
gcatatggac agtttccct ttgatatcta acgggtaaaca gttgttctac tttgtttgtt 6180
tagtcttgat gcttcactga tagatacaag agccataaga acctcagatc cttccgtatt 6240
tagccagttat gttctcttagt gttgtcggtt gttttgcgtt gaggccatgag aacgaaccat 6300
tgagatcatg cttaacttgc atgtcaactca aaaatttgc ctcaaaaactg gttagctgaa 6360
ttttgcgtt taaagcatcg tttttttttt ttcttagtcc gttacgtagg taggaatctg 6420
atgtaatgg tttttttttt ttgtcaccat ttttttttctt ctgggttgc tcaagttcgg 6480
ttacgagatc catttgcata tttttttttt tttttttttt caacgtatca gtcggggccgc 6540

ctcgcttatac aaccaccaat ttcatattgc tctaagtgtt taaatctta cttattgggt 6600
 tc当地aaaacccaa ttggtaaagc cttttaact catggtagtt attttcaagc attaacatga 6660
 acttaaattc atcaaggcta atctctatat ttgcctgtg agtittctt tggtagtt 6720
 ct当地ttataaa ccactcataa atccctcatag agtatttggtt tt当地aaaagac ttaacatgtt 6780
 ccagattata tt当地tatgaat tt当地taact ggaaaagata aggcaataatc tcttactaa 6840
 aaactaattc taattttcg cttgagaact tggcatagtt tgccactgg aaaatctcaa 6900
 agc当地tttaac caaaggattc ctgatttcca cagttctcg catcagctct ct当地tttgctt 6960
 tagctaatac accataagca tt当地ccctac tggtagttcat catctgagcg tattgggtt 7020
 aagtgaacga taccgtccgt tcttccctt tagggtttc aatcgtgggg tt当地tagtg 7080
 ccacacagca taaaattagc tt当地tttcat gctccgtttaa gtcatacgca ctaatcgcta 7140
 gttcatttgc tt当地aaaaca actaattcag acatacatct caattggctt aggtatttt 7200
 aatcactata ccaattgaga tgggctagtc aatgataatt actagtcctt tt当地tttgag 7260
 tt当地gggtat ctgtaaattc tggtagacct tt当地tgaaa acttgttaat tctgctagac 7320
 cctctgtaaa ttccgctaga ccttctgtg tt当地tttgt tt当地tttcaat gt当地ttataa 7380
 tt当地tagaat aaagaaaagaa taaaataaaaga taaaataaaat agatcccagc cctggttata 7440
 actactact tt当地tcagtt cc当地cgtatt acaaaaaggat gtc当地aaacg ct当地tttgctc 7500
 ct当地acaaaaa cagaccttaa aaccctaaag gcttaaattttag caccctcgca agctcggca 7560
 aatcgtgaa tattcccttt gt当地ccgacc atcaggcacc tggtagtcgtg tt当地tttgcgt 7620
 gacattcagt tc当地ctgcgt cacggctctg gc当地gttaatg ggggttaatg gc当地tacagg 7680
 cgc当地tttat ggattcatgc aaggaaacta cccataatac aagaaaagcc cgtc当地cggc 7740
 tt当地tcaggc gttttagtggc gggctgtcta tggtagttctt tctgactttt tgctggtt 7800
 cagttcctgc cctctgattt tccagttctga cc当地tcgga tt当地ccgtg acaggcattt 7860
 cagactggct aatgcacccaa gtaaggcagc ggtatcatca acaggcttac cc当地cttact 7920
 gtcaac 7926

<210> 25
 <211> 7701
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:glyA overexpression
 <223> plasmid

<400> 25
 gaattttgcg gccgcttcga aagctgtaat ataaaaaccc tcttcaacta acggggcagg 60
 tt当地gtgacat tagaaaacccg actgtaaaaaa gt当地cagtcgg cattatctca tattataaaa 120
 gca当地gtcatt aggccctatct gacaattcct gaatagagtt cataaaacaat cctgcatgt 180
 aaccatcaca aacagaatga tggtagttca aagatagcgg taaatatatt gaattacatt 240
 tattatgaa tt当地ctgtgt gt当地ataatgg gt当地ggta attactatta tt当地tttgcgt 300
 ttaatgtaaa cccagtaaat gaatccatg gaataataga aagagaaaaa gc当地tttcag 360
 gt当地taggtt tt当地ggaaac aatttccccg aaccattata tt当地cttaca tc当地aaagg 420
 ataaatcata aaactcttgc aagtcattct tt当地caggagt ccaaataccca gagaatgttt 480
 tagatacacc atcaaaaatt gt当地aaatgt gctctactt atcccaataaa octaactctc 540
 cgtogctatt gtaaccaggctt ctaaaaggctg tatttggat tatttgcctt gtc当地actaga 600
 aaataaatgc agggtaaaat tt当地atcctt ct当地gtttt gtttccgtat aaaacactaa 660
 tat当地atttc tggtagttata ctaaaaggctg tt当地gttgggtt caaataatga tt当地atct 720
 ct当地ttctt ccaattgtct aaatcaattt tatttggat catttgcgtat gc当地cttcaa 780
 tt当地ttatcta aagtgtat tt当地gggtt cttgtctgtt tt当地tcttcaat gaatcaatcc 840
 tt当地ttttaaa gtc当地atatta ct当地aacata aatataatatt tt当地aaatat cccactttat 900
 ccaattttcg tt当地gttgcac taatgggtgc tt当地gttgc gataaaaagac cacattaaaa 960
 aatgtggctt tt当地gttgc tt当地aaaggat tt当地ggctt cggaaaaatcc tt当地tttctt 1020
 tat当地tgcata ataagggtaa ct当地ttgtatt cggtagccaa agt当地ttgtt aacgc当地aaaaa 1080
 ggccatccgt caggatggcc tt当地gttcaat tt当地gttgcctt ggc当地gtt ggc当地ggcgtc 1140
 ct当地ccggca cc当地ccggcc cgttgcctcg caacgttcaa atccgttccc ggc当地ggatttgc 1200
 tc当地ctactcag gagagcgttc accgacaaaac aacagataaa acgaaaggcc cagtc当地ttcg 1260
 actgagcctt tc当地ttttatt tggtagttcatg cttgttccatc ct当地tgc当地at gggagacccc 1320
 acactaccat cggc当地ctacg gc当地tttact tctgaggctg gcatggggtc aggtgggacc 1380
 accgc当地ctac tggccccagg ctaattctgt tt当地atcagac cgcttctgcg tt当地gttcaat 1440

atctgtatca ggctgaaaat cttctctat ccggccaaaac aggatcccc atcaacaatt .1500
acacacttct attgattcta caaaaaaaga cattgagttt caagaacatc gtcaaaaaac 1560
ccgcggca taagcccaag cggttttag gatcttaata atctaattct ttatataaag 1620
gaaatttatac agtcagagca gctacacgct gtcttgcttc ttcaagttt ccttcatctt 1680
cggtgtttt caatgcaagc gcaatgatag caccgacttc ttctaatgcg tctccgtcaa 1740
aaccgcggct gtttacagca gctgtaccaa gacggatgcc gcttgttacg aaaggtttt 1800
caggatcata tggaaatcgcg ttttgttag acgtaatacc aatttcatca agtacatgct 1860
ccgcaacctt accagtcagt ccgagcgaac gaaggtaac aaggataagg tggttgtctg 1920
ttccgcctga aacgagctgg atgcccctt tcgttaaggc ttccagccaga cgtttgcgt 1980
ttgaaatgac gtttgtgca tatgtttga aatcgctctg caataacttca ccgaatgaaa 2040
cagctttgc ggcaataacg tgcatcagag ggccgcctt aattccagg aagatcgatt 2100
tatcaattttt ctgc当地aaac tcttcacggc aaaggatcat accgc当地gaa ggaccgc当地 2160
gtgtttatg tggtgttggta acgtcaagg aaccgggttt ggatgaaggc 2220
ctggc当地caac aagtccgtcg atatgtccca tatccaccat gaagtaagcg ccgacttcat 2280
cagaatttc acggaatttc taaaagtgcg ttgtacgagg atacgcactt gctccgtct 2340
cgataagctt cgggttatgca gcgagggtt ttccacgcac gtc当地gttaa tcaatataatt 2400
gagttctttt atctacgccc tactcaacaa agttatattt aacaccgctg aagttgactg 2460
ggcttccgtg tgtaaatgg cc当地ccgtggg agaggttcat cccaaatgaca gtatccctt 2520
gctccaaaat cgtgaagtac actgc当地atgt ttgc当地gtgc gc当地taatga ggctgaacgt 2580
ttacatgctc cgctccaaag attcccttgc cgccggtcact ggccgatatact tcaacgacat 2640
cgacgtgctc gcatccccc tagtagcgtt tgccggata tccttctgcg tacttattt 2700
tcaaaacaga tccttgc当地 tccataaccg cttcacttac aaagttctca gaagcaatca 2760
attcgatctt agtctgttgg cgttacgc当地 catttttaat ggctttaaac acttgc当地t 2820
cttgc当地cagg taaatgttcc atgttacac ctc当地ttaga gc当地ctgc当地 gttgttaaga 2880
ttattatacc acaccttgc当地 gataaaagtc当地 acaactttt gcaaaatttt tc当地ggaaattt 2940
tagcagagg tggatgttggat gt当地aaacaaa acatcttcc gcttgc当地 tggatggata 3000
tcttcttgg aagcttagtgc当地 ggctc当地gact tatggc当地gtt ggttaaaagg aaacaaaagg 3060
accgtttca cacaaaacgg tcttttgc当地 ttcttttta cagtc当地acgc cactttgc当地 3120
aaaaccggac agcttcatgc ct当地ataactg ctgtttgc当地t cgacaagctt cgccgaaacgg 3180
ccgcaaaattt cactggccgt cgttttacaa cgtcgtact gggaaaaccc tggc当地ttacc 3240
caacttaatc gc当地tgc当地c acatccccctt ttccgc当地actt ggctgtaatag cgaagaggcc 3300
cgccaccgatc gcccttccca acagttgc当地t agcctgaaatg gcaatggcc cctgatgc当地 3360
tatttctcc ttacgc当地tct gtgc当地gttatt tc当地accgc当地a tatggtgc当地tctc当地t 3420
atctgctctg atgccc当地ata gttaaaggccag cccc当地gacacc cgccaaacacc cgctgactat 3480
gcttgc当地aaac cgttttgc当地 aaaaatttt aaaataaaaaa aggggacctt tagggtcccc 3540
aattaatttag taatataatc tattaaaggc当地t cattccaaaatg gtc当地atccacc ggatc当地gctt 3600
agtaaaaggccc tc当地cttagatt ttaatgc当地ga tggatgtgc当地t acttc当地ccaa ctattgc当地t 3660
aacaagaaaa agccaggctt tcatgatata tctcccaatt tggatgtggc ttattatgc当地 3720
cgcttaaaaaa taataaaaggc agacttgc当地t tggatgttgc当地t gcttgc当地gca attatgtct 3780
tagtgc当地tct aacgcttgc当地t ttaagccgc当地t cc当地cgaaagcg gcttgc当地gtt gaaacgaaattt 3840
tttagacatta ttgc当地gc当地t accttggc当地t tctgc当地ctt cacttgc当地tgg acaaatttctt 3900
ccaactgatc tgccglocalgag gccaaggc当地t ttcttcttgc当地t tccaaagatataa gc当地tgc当地t 3960
cttcaagatc gacgggctgc当地t tactggccgc当地t gcaggc当地tctc cattgc当地ccag tc当地ggc当地agc当地 4020
catcccttc当地gg cgc当地gttatttgc当地t cc当地gttactgc当地t cgctgtaatcc aacgtaagca 4080
ctacatttgc当地tctc catgc当地ccca gccc当地gttccgg gccc当地gttccgg ccatagc当地tctt aagggttcat 4140
tttagc当地gc当地tctc aaatagatcc tggatgtggaa cc当地gttccaa gagtttgc当地tcc gccglocalgag 4200
ctaccaaggc当地t aacgctatgt tcttgc当地tctt ttgtc当地gcaatgc当地t gatagccaga tcaatgtc当地t 4260
tc当地tggctgg ct当地gaagata cctgc当地agaa tggatgtggcc localtgc当地t ctgccatttctt ccaaatttgc当地a 4320
gttgc当地gttcc agcttgc当地ttaa cc当地ggccggaa tggatgtgc当地t gtc当地acaaca atgggtgactt 4380
ctacagc当地gc当地c gagaatctcg ctctctccag gggaaaggccgaa agtttccaaa aggtc当地gttgc当地t 4440
tcaaaaggctcg cc当地cggttgc当地t tcatcaagcc localtgc当地tacgc当地t cgttaccgc当地t aatcaatataat 4500
caacttgc当地tgg ct当地caggccg ccatccactg cc当地ggccgtt caaatgtacg gccagcaacgc 4560
tc当地gttgc当地tcc agtgc当地ctcg atgacgc当地aa ctaccttgc当地t tagttgc当地tctt gataacttgc当地 4620
cgatcaccgc当地tccctcatg atgtttaact ttgttttagg gcttgc当地tcc gtc当地gttgc当地t 4680
catcgttgc当地t gctccataac atcaaaacatc gacccacggc当地t gtaacgc当地gttgc当地t tgctgcttgg 4740
atgccc当地ggagg catagactgtt accccaaaaccc aacagtc当地tata acaaggccatg aaaaccgc当地a 4800
ctgccglocalgtt accaccgc当地tcc cgttgc当地tca aggttgc当地tgg ccaggccgtt gacgc当地tatac 4860
gctacttgc当地tta ttagacttgc当地tta cgaaccgc当地a accgttgc当地tcttgc当地t ccacttgc当地tgg 4920
tccglocaltccca cggatgtgc当地tctt caccggccaa ccttgc当地tggccag cagc当地gaatgc当地t gaggcatttgc当地 4980

tgtcctggct ggcgaacgag cgcaagggtt cggtctccac gcatcgtaq gcattggcgg 5040
 ccttgctgtt cttctacggc aaggtgctgt gcacggatct gccctggctt caggagatcg 5100
 gaagacctcg gccgtcgccg cgcttgcggg tggtgctgac cccggatgaa gtggtcgca 5160
 tcctcggtt tctggaaggc gagcatcggt tggtcgccca gottctgtat ggaacgggca 5220
 tgccgatcg tgagggtttg caactgcggg tcaaggatct ggatttcgat cacggcacga 5280
 tcatcggtcg ggagggcaag ggctccaagg atcgggcctt gatgttaccc gagagcttgg 5340
 caccacgct ggcgcgacag gggaaattgat ccgggtggatg acctttgaa tgacctttaa 5400
 tagattatat tactaattaa ttggggaccc tagaggtccc ctttttattt taaaaaattt 5460
 tttcacaaaaa cggttacaa gcataacggg ttttgcgcc cgcaaacggg ctgttctgg 5520
 gttgcttagtt tgttatcaga atcgcagato cggcttcagg ttgcggcgt gaaagcgcta 5580
 tttcttcag aattgccatg atttttccc cacgggaggc gtcactggct cccgttgg 5640
 cggcagctt gattcgataa gcagcatcgc ctgtttcagg ctgtctatgt gtgactgtt 5700
 agctgtaca a gttgtctca ggtgttcaat ttcatgttct agttgttgg tttactgg 5760
 ttcacctgtt ctattaggtg ttacatgctg ttcatctgtt acattgtcga tctgttcatg 5820
 gtgaacagct taaaatgcac caaaaactcg taaaagctct gatgtatcta tctttttac 5880
 accgtttca tctgtgcata tggacagttt tcccttgcgt atctaacggt gaacagttgt 5940
 tctacttttgc ttgttagtgc ttgtatgcctc actgatagat acaagagcca taagaaccctc 6000
 agatcctcc gtatttagcc agtatgttct ctatgttgg tcgttggg tgcgtgagcc 6060
 atgagaacga accattgaga tcatgtttac ttgcattgtc actcaaaaat ttgcctcaa 6120
 aactggtagg ctgaattttt gcagttaaag catcgtagt tagttttctt agtccgttac 6180
 gtaggttagg atctgatgtt atgggttgg gtattttgtc accattcatt ttatctgg 6240
 tgttctcaag ttcgggttacg agatccattt gtctatctag ttcaacttgg aaaatcaacg 6300
 tatcagtccg gcggcctcgc ttatcaacca ccaatttcat attgctgtaa gtgtttaaat 6360
 ctttacttat tggtttcaaa acccatttgtt taaggccttt aaactcatgg tagtttttt 6420
 caagcattaa catgaactta aattcatcaa ggctaatctc tatatttgc ttgtgagttt 6480
 tcttttgtt tagttcttt aataaccact cataaaatctt catagagtat ttgtttcaa 6540
 aagacttaac atgttccaga ttatatttt tgaattttt taactggaaa agataaggca 6600
 atatctcttc actaaaaact aattctaatt ttcgcttga gaacttggca tagtttgtcc 6660
 actggaaaat ctcaaaaggct ttaacccaaag gattcctgtat ttccacagt tctgtcatca 6720
 gctctctggt tgcttttagt aatacaccat aagcattttc cctactgtat ttcatcatct 6780
 gagcgtattt gttataagtg aacgataccg tccgttctt cttgttaggg ttgttcaatcg 6840
 tgggtttagg tagtgccaca cagcataaaa tttagtctgtt ttcatgtctc gttaaagtcat 6900
 agcactaat cgcttagttca ttgcatttga aaacaactaa ttccagacata catctcaatt 6960
 ggtctagggtt attttaatca ctataccaaat tgagatggc tagtcaatga taattactag 7020
 tcctttctt ttgagttgtt ggtatctgtt aattctgttca gacctttgtt ggaaaacttg 7080
 taaattctgc tagaccctct gtaaaattccg cttagacctt gtgttggg tttgtttata 7140
 ttcaagtggt tataatttat agaataaaaga aagaataaaaa aaagataaaaa agaataagatc 7200
 ccagccctgt gtataactca ctacttttagt cagttccgca gtattacaaa aggatgtcgc 7260
 aaacgctgtt tgctcctcta caaaaacagac cttaaaaaccc taaaggcttta agtagcacc 7320
 tcgcaagctc gggcaaatcg ctgaatatto ctttgttctc cgaccatca gCACCTGAGT 7380
 cgctgtctt ttgcgtgacat tcagttcgct ggcgtcacgg ctctggcagt gaatgggggt 7440
 aaatggcact acaggcgctt tttatggatt catgcaagga aactaccat aatacaagaa 7500
 aagccccgtca cgggcttctc agggcgtttt atggcgggtc tgctatgtgg tgctatctga 7560
 cttttgcgtt ttgcgtgacat cctgcctct gattttccag tctgaccact tcggattatc 7620
 ccgtgacagg tcattcagac tggctaatgc acccagtaag gcagcggtat catcaacagg 7680
 cttaaccgtc ttactgtcaa c 7701

<210> 26
 <211> 3888
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> plasmid

<400> 26
 tgcccgcta cagggcgctt ccattcgcca ttcaaggctgc gcaactgttg ggaagggcga 60
 tcggtgcggg cctcttcgtt attacgcccag ttgggggtt agttcatgaa gtttcgtcgc 120
 agccgcgat tggtgactt aacaaattat ttgttaaccc atccgcacga gttaaataccg 180

ctaaccttt tctctgagcg gtagaatct gcaaaatcat cgatcagtga agattaaca 240
 attattaaac aaacctttga acagcagggg attggtaactt tgcttactgt tcccgagct 300
 gccggaggcg taaaatatat tccgaaaatg aagcagctg aagctgaaga gtttgccag 360
 acacttggac agtcgctggc aaatcctgag cgtatcctc cgggcggta tgtatattta 420
 acggatatct taggaaagcc atctgtactc tccaaggtag ggaagctgtt tgcttccgt 480
 tttgcagagc gcgaaatgtg tggtaatcg accgttccca cggaaaggcat ccctcttgcg 540
 tacgcagctg caagcttattt gaatgtgcct gttgtatcg ttctgtaaaga caataaggta 600
 acagagggtc ccacagtcg catataattac gtttcaggct cctccaaaccg cattcaaaca 660
 atgtcacttg cgaaaagaag catgaaaacg gttcaaacg tactcattat tgatgacttt 720
 atgaaaagcag gcgccaccat taatggatg attaacctgt tggatgagtt taacgcaaat 780
 gtggcggaa tcggcgtctt agtgaagcc gaaggagtag atgaacgtct tggatgacaa 840
 tatatgtcac ttcttactct ttcaaccatc aacatgaaag agaagtccat tgaaattcag 900
 aatggcaatt ttctgcgtt tttaaagac aatctttaa agaatggaga gacagaatca 960
 tgacaaaagc agtccacaca aaacatgccc cagcggcaat cgggccttat tcacaaggaa 1020
 ttatcgtaa caatatgttt tacagctcg gccaaatccc tttgactcct tcaggcgaaa 1080
 tggtaatgg cgatattaag gggcagactc atcaagtatt cagcaattta aaggcggttc 1140
 tggaaagaagc ggggtcttctt tttgaaaacg ttgtaaaagc aactgttattt atcgccgata 1200
 tggAACAGTT tgcggaaatg aacaaggatgt acggacaata ttttgacact cacaaccgg 1260
 cgagatcttgcgtt gttgaagtc gcggactcc cgaaggatgc gtttagtgcgat atcgaagtt 1320
 ttgcactggc gaaataataa gaaaagtgtat tctggagag cccggatcac ttttttattt 1380
 accttatgcc cgaaaatgaaa gctttatgac cctgcattaa tgaatcggcc aacgcgcggg 1440
 gagaggcggt ttgcgttattt ggcgtcttc cgcttcctcg ctcaactgact cgctgcgtc 1500
 ggtcggttcgg ctgcggcgag cggatcagc tcactcaaag gcggtataac gtttatccac 1560
 agaatcaggc gataacgcag gaaagaacat gtgacaaaaa gcccggcaaa aggccaggaa 1620
 ccgtaaaaag gccgcgttgc tggcggtttt cgataggctc cggccccctg acgagcatca 1680
 caaaaatcgatcgatcaggc agagggtggcg aaaccggaca ggactataaa gataccaggc 1740
 gtttccccctt ggaagctccc tcgtgcgtc tcctgttccg accctgcgcg ttaccggata 1800
 cctgtccgccc ttctccctt cggaaagcgt ggcgtttct catagctcac gctgttaggt 1860
 tctcagttcg gtgttaggtcg ttgcgtccaa gctgggtgt gtgcacgaa ccccggtca 1920
 gcccggaccgc tgccgttat ccgttaacta tcgtcttgcg tccaaccgg taagacacga 1980
 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgttaggcgg 2040
 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg 2100
 tatctgcgtc tgcgtgaagc cagttacctt cggaaaaaga gttggtagct ttgtatccgg 2160
 caaacaacc accgctggta gcgggtgtt ttttgttgc aagcagcaga ttacgcgcag 2220
 aaaaaaaagga tctcaagaag atcctttgtat ctttctacg gggctctgacg ctcagtgaa 2280
 cgaaaactca cgttaaggga ttttggatcat gagattatca aaaaggatct tcaccttagat 2340
 ccttttaat taaaatgaa gttttaatc aatctaaatg atatatgatgaa aacttggtc 2400
 tgacagttaa caatgtctaa tcagtggaggc acctatctca gcgatctgtc tatttcgttc 2460
 atccatagtt gcctgactcc ccgtcggtt gataactacg atacggggagg gcttaccatc 2520
 tggcccccagt gctcaatga taccggaga cccacgtca cccggctccag atttatcagc 2580
 aataaaaccag ccagccggaa gggccggagc cagaagtggt cctgcaactt tatccgcgtc 2640
 catccagtct attaattgtt gccggaaagc tagagtaatg agttcgccag ttaatagttt 2700
 ggcgaacgtt gttggatttgc ctacaggcat cgtgggtgtca cgctcggtcg ttggatggc 2760
 ttcattcagc tccgggttttcc aacgatcaag gcgagttaca tgcgttttttca tggatggca 2820
 aaaagcggtt agtccttcg gtcctccgat cttgttcaga agtaagtgg ccgcagtgtt 2880
 atcactcatg gttatggcag cactgcataa ttcttactt gtcatgccc ccgtaaatgt 2940
 cttttctgtt actgggtgagt actcaaccaa gtcatttgcgaaatcccgcccccggacc 3000
 gagttgtct tggccggcgtaatcgggaa taatgtgtat gacatagca gaaatggaaa 3060
 agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgtgtt 3120
 gagatccagt tcgatgttaac ccactcggtc acccaactga ttttcagcat ttttacttt 3180
 caccagcggtt tctgggtgag cggaaatcgggaaaggcaaaat gccggcaaaaaa agggataaag 3240
 ggcgacacgg aaatgttggaa tactcatact tttccctttt caatattttt gaaatggat 3300
 tcagggttat tgcgtcatga gcgatcatac atttgaatgt atttagaaaa ataaacaaat 3360
 aggggttccg cgcacatttc cccggaaaatg gccacgtca tgggtgtga aataccgcac 3420
 agatgcgtaa ggagaaaaata ccgcgttccgg cggaaatgtt aacgttaata ttttggaaa 3480
 attcgcgtta aatattttgtt aatcagctc atttttttaac caataggccg aaatccggca 3540
 aatcccttat aatcaaaaag aatagaccga gatagggttg agtggatgtt cagttggaa 3600
 caagagtcca ctattaaaga acgtggactc caacgtcaaa gggcgaaaaa ccgtctatca 3660
 gggcgatggc ccactacgtg aaccatcacc caaatcaagt ttttgcggc 3720

taaaagctcta aatcggaacc ctaaaaggag ccccccattt agagcttgac ggggaaagcc 3780
ggcgaacgtg gcgagaaaagg aagggaagaa agcgaaagga gcgggcgcta gggcgctggc 3840
aagtgttagcg gtcacgctgc gcgttaaccac cacacccgcc gcgcttaa 3888

<210> 27
<211> 4606
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:plasmid

<400> 27
tgcggcgata cagggcgcg ttcaggctgc gcaactgttg ggaagggcga 60
tcgggtcgaaa cctcttcgtt attacgcccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgcccagg gtttccccag tcacgacgtt gtaaaacgcac ggccagtgaa 180
ttgttaatacg actcactata gggcgaattt gggccgacgt cgcatgctcc cggccgccccat 240
ggcccgccggg tgcggcccg tgcacgtgaa ataccgcaca gatgcgttaag gagaaaatac 300
cgcatcaggc gataaaccca gcaaccatt tgagggtata ggtaagattt taccgaggta 360
tgaaaacggag aattggaccc ttacagaattt actctatgaa ggcctatattt taaaaagctt 420
ccaagacgaa gaggatgaaag aggatgagga ggcagattgc cttgaatata ttgacaatac 480
tgataagata atatatcttt tatataagaag atatcgccgt atgttaaggat ttcagggggc 540
aaggcatagg cagcgccgtt atcaatataat ctatagaatg ggcaaaggcat aaaaacttgc 600
atggactaat gcttggaaacc caggacaata accttatagc ttgttaattt tatacataatt 660
gtgtttcaaa aatcggtctt gtcgataacta tttttttttt caacttttcaaa aacaactttt 720
aaaaagctgt tttctggat ttaagggtttt agaatgcac gaaacagtggaa ttggagttcg 780
tctgttata attagcttct tgggtatct ttaaataactg tagaaaagag gaagaaaata 840
ataaatggct aaaatgagaa tttttttttt tttttttttt tttttttttt tttttttttt 900
cgtaaaaagat acggaaggaa tttttttttt tttttttttt tttttttttt tttttttttt 960
aaacctatataat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1020
ggaaaaggac atgatgttat tttttttttt tttttttttt tttttttttt tttttttttt 1080
tgaacggcat gatggcttggaa gcaatctgtt catgagtggaa ggcgtatggc tttttttttt 1140
ggaagagttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1200
cagctctttt cactccatcg acatatcgga tttttttttt tttttttttt tttttttttt 1260
cttagccgaa ttggattact tactgaataa cttttttttt tttttttttt tttttttttt 1320
ggaagaagac actccattttt aagatcccgcc tttttttttt tttttttttt tttttttttt 1380
gcccgaagag gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1440
agatggcaaa gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1500
tgacatttgcctt ttctgcgtcc ggtcgatcgtt tttttttttt tttttttttt tttttttttt 1560
gtttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1620
actggatgaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1680
tttagacatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1740
tctttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1800
ttcgccattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1860
agtgcggcccg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1920
tgagtattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 1980
tgtgaaattttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2040
aaggctgggg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2100
ctttccatcg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2160
gaggcggtttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2220
tcgtttcggtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2280
aatcaggggaa tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2340
gtaaaaaggcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2400
aaaatcgacg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2460
ttccccctgg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2520
tgtccgcctt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2580
tcagttcggtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2640
ccgaccgctg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2700
tatcgccactt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 2760

ctacagagtt cttgaagtgg tggcctaact acggctacac tagaaggaca gtatttggta 2820
 tctgcgtct gctgaaggcca gttaccttcg gaaaaagagt tggtagctct tgatccggca 2880
 aacaaaccac cgctggtagc ggtggtttt ttgttgc当地 gcagcagatt acgcgcagaa 2940
 aaaaaggatc tcaagaagat ccttgc当地 tttctacggg gctctgacgc cagtgaaacg 3000
 aaaactcagc ttaagggatt ttggcatga gattatcaa aaggatctt acctagatcc 3060
 ttttaaatta aaaaatgaagt tttaaatcaa tctaaatgat atatgagtaa acttggctcg 3120
 acagttacca atgcttaatc agtgaggcac ctatctcagc gatctgtcta ttgc当地 3180
 ccatagttgc ctgactcccc gtcgtgtaga taactacat acgggaggcc ttaccatctg 3240
 gcccagtgc tgcaatgata cccgc当地 accgctcacc ggctccagat ttatcagcaa 3300
 taaaccagcc agccggaagg gccgagc当地 gaagtggtcc tgcaacttta tccgc当地 3360
 tccagtctat taattgttgc cgggaagcta gagtaatgat ttgc当地 3420
 gcaacgttgt tggc当地 acaggcatcg tggc当地 3480
 cattcagctc cggcc当地 ccatcgatc gagttacatg atccccatg ttgtgcaaaa 3540
 aagcggttag ctccctcggc cctccgatcg ttgtc当地 3600
 cactcatgt tatggc当地 ctgc当地 att ctcttactgt catgccatcc gtaagatgct 3660
 tttctgtgac tggc当地 3720
 gttgctctg cccggc当地 atacgggata atagtgtatg acatagcaga actttaaaaag 3780
 tgctcatcat tggaaaacgt tctc当地 3840
 gatccagttc gatgttaaccc actcgtgc当地 ccaactgatc ttgc当地 3900
 ccagcgttcc cggc当地 3960
 cgacacggaa atgttgaata ctctactct tc当地 4020
 agggttattt tctcatgagc ggatacatat ttgaatgtat tttagaaaaat aaacaaaatag 4080
 gggccgc当地 cacatttccc cggc当地 4140
 atgc当地 4200
 tc当地 4260
 tcccttataa atcaaaaagaa tagaccgaga tagggttgc当地 4320
 agagtccact attaaagaac gtggacttca acgtcaaaaagg gcaaaaaacc gtctatcagg 4380
 gcgatggccc actacgtgaa ccatcacccaa atcaagttt ttgc当地 4440
 aagctctaaa tc当地 4500
 cgaacgtggc gagaaaggaa gggc当地 4560
 gtgttagcggt caccgctglocal gtaaccacca caccgc当地 4606

<210> 28

<211> 5399

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 28

tgc当地 caggc当地 cgttccatcc ttccggctgc gcaactgttg ggaaggccga 60
 tc当地 cctcttc当地 attacgccag ttgggggtg agttcatgaa gttc当地 120
 agccgc当地 tggc当地 180
 ctaacctttt tctctgagcg gtatgaatct gcaaaatcat cgtc当地 agatttaaca 240
 attattaaac aaaccttttga acacgagggg attggtaactt tgcttactgt tccc当地 300
 gccggaggccg ttaaaatataat tccgaaaatg aacgaggctg aagctgaaaga gttt当地 360
 acacttggac agtc当地 420
 acgatatct taggaaagcc atctgtactc tccaaggtag ggaagctgtt tgcttccgtg 480
 ttgc当地 540
 tacgc当地 600
 taccgaggta tgaaaacgag aattggacct ttacagaatt actctatgaa gccc当地 660
 taaaagctt ccaagacgaa gaggatgaag aggatgagga ggc当地 720
 ttgacaatac tgataagata atatatctt tatatagaag atatcgccgt atgtaaggat 780
 ttcaaggggc aaggcatagg cagc当地 840
 aaaaacttgc atggactaat gctt当地 900
 tatac当地 960
 aacaactttg aaaaagctgt ttctggat ttaaggttt agaatgcaag gaacagtgaa 1020
 ttggagttcg tctt当地 1080

aaggaaata	ataaatggct	aaaatgagaa	tatcaccgga	attaaaaaa	ctgatcgaaa	1140
aataccgctg	cgtaaaagat	acggaaggaa	tgtctcctgc	taagtatat	aagctggtgg	1200
gagaaaatga	aaacctatat	ttaaaaatga	cgacagccg	gtataaaggg	accacctatg	1260
atgttgcacg	ggaaaaggac	atgatgctat	gcttggaaagg	aaagctgcct	gttccaaagg	1320
tcctgcactt	tgaacggcat	gatggcttga	gcaatctgt	catgagttag	gccatggcg	1380
tccttgctc	ggaagagtat	gaagatgaac	aaagccctga	aaagattatc	gagctgtatg	1440
cgagtgcat	caggctttt	caactccatcg	acatatcgaa	ttgtccctat	acgaataagct	1500
tagacagccg	cttagccgaa	ttggattact	tactgaataa	cgatctggcc	gatgtggatt	1560
gcgaaaactg	ggaagaagac	actccattta	agatcccg	cgagctgtat	gattttttaa	1620
agacggaaaa	gcccgaaagag	gaacttgtct	tttcccacgg	cgacctggga	gacagcaaca	1680
tctttgtgaa	agatggcaaa	gtaagtggct	ttattgtatc	tgggagaagc	ggcaggccgg	1740
acaagtggta	tgacattgcc	ttctgcgtcc	ggtcgatcag	ggaggatatc	ggggagaac	1800
agtatgtcga	gctattttt	gacttactgg	ggatcaagcc	tgattgggag	aaaataaaat	1860
attatatttt	actggatgaa	ttgttttagt	acctagattt	agatgtctaa	aaagctttaa	1920
ctacaagctt	tttagacatc	taatcttgc	tgaagtagatc	ccgcaactgt	ccatactctg	1980
atgtttata	tctttctaa	aagttcgcta	gataggggtc	ccgagcgcct	acgaggaatt	2040
tgtatcacca	ggtaccagct	gcaagctatt	tgaatgtgcc	tgttgtgatc	gttcgtaaag	2100
acaataaggt	aacagagggc	tccacagtca	gcattaattt	cgtttcaggc	tcctcaaacc	2160
gcattcaaac	aatgtcactt	gcaaaaagaa	gcatgaaaac	gggtcaaac	gtactcatta	2220
ttgatgactt	tatgaaagca	ggcggccacca	ttaatggtat	gattaacctg	ttggatgagt	2280
ttaacgaaa	tgtggcgaaa	atcggctct	tagttaagc	cgaaggagta	gatgaacgtc	2340
ttgttgcacg	atataatgtca	cttcttactc	tttcaaccat	caacatgaaa	gagaagtcca	2400
ttgaaattca	gaatggcaat	tttctgcgtt	tttttaaaga	caatctttt	aagaatggag	2460
agacagaatc	atgacaaaag	cagtccacac	aaaacatgcc	ccagcggcaa	tcgggcctt	2520
ttcacaaggg	attatcgca	acaatatgtt	ttacagctca	ggccaaatcc	cttgactcc	2580
ttcaggcgaa	atggtaatgt	gcatattaa	ggagcagact	catcaagttt	tcagcaattt	2640
aaaggcggtt	ctggaagaag	cgggtcttc	tttggaaaca	gtttaaaaag	caactgtatt	2700
tatcgccgt	atggaacagt	ttgcggaaat	aaacgaagtg	tacggacaat	attttgacac	2760
tcacaaaccg	gcgagatctt	gtgttgaatg	cgcgagactc	ccgaaggatg	cgtagtgcg	2820
gatogaagtt	attgcactgg	tgaataata	agaaaaagtg	ttctggaga	gccggatca	2880
cttttttatt	taccttatgc	ccgaaatgaa	agctttatga	ccctgcattt	atgaatcggt	2940
caacgcgcgg	ggagaggcgg	tttgcgtatt	gggcgcttct	ccgcttcctc	gctcaetgac	3000
tcgctgcgct	cggcgttcc	gctgcggcga	ggggatcag	ctcactcaaa	ggcggtataa	3060
cggttatcca	cagaatcagg	ggataacgca	gaaaagaaca	tgtgagcaaa	aggccagcaa	3120
aaggccagga	accgtaaaaa	ggccgcgtt	ctggcgtttt	tcgataggct	ccgccccct	3180
gacgagcatc	acaaaaatcg	acgctcaagt	cagaggtggc	gaaacccgac	aggactataa	3240
agataccagg	cgtttcccc	ttggaaatctc	ctcgatgcgt	ctccgttcc	gaccctgccc	3300
cttacccggat	acctgtccgc	ctttctccct	tcgggaagcg	tggcgtttc	tcatagctca	3360
cgtcttaggt	atctcagttc	ggtgttaggtc	tttcgcttca	agctgggctg	tgtgcacgaa	3420
ccccccgttc	agccccgaccc	ctgcgcctta	tccggtaact	atcgcttgc	gtccaacccg	3480
gtaagacacg	acttatacgcc	actggcagca	gccactggta	acagattag	cagagcggagg	3540
tatgttaggcg	gtgctacaga	gttcttgcag	ttgtggccctt	actacggctt	cactagaagg	3600
acagtatttg	gtatctgcgc	tctgttgcag	ccagttactt	tcggaaaaag	agttggtagc	3660
tcttgcacgg	gcaaaacaaac	caccgttgcgt	agcgggtttt	ttttgtttt	caagcagcag	3720
attacgcgc	gaaaaaaaaag	atctcaagaa	gatcccttgc	tctttctac	ggggtctgac	3780
gctcgttgg	acgaaaaactc	acgtttaagg	attttggtca	tgagattatc	aaaaaggatc	3840
ttcacctaga	tccttttaaa	ttaaaaatga	agtttttaat	caatctaaag	tatatatgag	3900
taaacttgg	ctgacagttt	ccaatgttta	atcagttaggg	cacctatctc	agcgatctgt	3960
ctatccgtt	catccatagt	tgcctgactc	cccgctgtgt	agataactac	gatacgggag	4020
ggcttaccat	ctggccccag	tgctgcaatg	ataccgcgag	accacgcctc	accggctcca	4080
gatttatcg	caataaacc	gccagccgga	agggccgagc	gcagaagtg	tcctgcaact	4140
ttatccgcct	ccatccagtc	tattaattgt	tgccgggaag	ctagagtaag	tagtcgcca	4200
gttaatagtt	tgcgcaacgt	tgttggcatt	gctacaggca	tcgttgttgc	acgctcgctg	4260
tttggatgg	cttcattca	ctccggttcc	caacgatcaa	ggcgagttac	atgatcccc	4320
atgttgcac	aaaaagcggt	tagctcttc	ggtcctccga	tcgttgtcag	aagtaagtgt	4380
gcccgcagtgt	tatcactcat	ggttatggca	gcaactgcata	attctcttac	tgtcatgcca	4440
tccgttaagat	gctttctgt	gactggtag	tactcaacca	agtcttctg	agaataccgc	4500
gcccggcgac	cgagttgctc	ttgcccggcg	tcaatacggg	ataatagtgt	atgacatagc	4560
agaactttaa	aagtgtctcat	cattggaaaa	cgtttctcgg	ggcggaaaact	ctcaaggatc	4620

ttaccgcgtg tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca 4680
tctttactt tcaccacgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa 4740
aaggaaataa gggcgacacg gaaatgttga atactcatac tcttccttt tcaatattat 4800
tgaagcatt atcagggta ttgtctcatg agcggataca tatttgaatg tatttagaaa 4860
aataaacaaa taggggttcc gcgcacattt ccccggaaaag tgccacctgt atgcgggttg 4920
aaataccgca cagatgcgt aagagaaaat accgcacatcg gcgaaattgt aaacgttaat 4980
atttgttaa aattcgcgtt aaatatttgc taaatcagct catttttaa ccaataggcc 5040
gaaatcgca aaatcccta taaatcaaaa gaatagaccg agatagggtt gagtgttgtt 5100
ccagtttggg acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa 5160
accgtctatc agggcgatgg cccactacgt gaaccatcac ccaaatacaag tttttgcgg 5220
tcgaggtgcc gtaaagctt aatcggaac cctaaaggga gcccccgatt tagagcttga 5280
cggggaaagc cgccgaacgt ggcgagaaaag gaagggaga aagcgaaagg agcgggcgt 5340
agggcgctgg caagtgttagc ggtcacgctg cgcgtAACCA ccacacccgc cgcgttaa 5399

<210> 29
<211> 6805
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:plasmid

<400> 29
ttgcggccgc ttcaaaagct gtaatataaa aaccttcttc aactaacggg gcaggtagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttctgaata gagttcataa acaatctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaaccacag taaatgaagt ccatgaaata atagaaagag aaaaagcatt ttcaaggata 360
ggtgttttgg gaaacaattt ccccgAACCA ttatatttct ctacatcaga aaggtataaaa 420
tcataaaact ctttgaagtc attctttaca ggagtccaaa taccagagaa tgtttttagat 480
acaccatcaa aaattgtata aagtggctt aacttatccc aataaacctaa ctctccgtcg 540
ctattgtAACACAGAGTTTCTAAAGCTGTATTGAGTTTATCA CCCTTGTCAC TAAGAAAATA 600
aatgcagggt aaaatttata tccttcttgc ttatgtttc ggtataaaaac actaatatca 660
atttctgtgg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaaat tgcgtAAATC AATTTATTA AAGTTTATTG GATATGCCTC CTAATTTTTT 780
atctaaagtg aatTTAGGAG GCTTACTTGT CTGCTTCTT CATTAGAATC AATCCTTTT 840
taaaagtcaa tattactgt aacataaatat atattttaaa aatatccac ttatccaat 900
tttcgtttgt tgaactaatg ggtgttttag ttgaagaata aagaccacat taaaaaatgt 960
ggttttttgt gtTTTTTAA AGGTTTGTAG CGTAGCGAAA AATCCTTTTCTTCTTCTT 1020
tgataataag ggtAAACTTGAATTCGGTA CCAAGAGTTG TGTAAACGC AAAAAGGCCA 1080
tccgtcagga tggccttctg cttaatttgc tgccctggcag ttatggcgg gcgtcctgcc 1140
cgccaccctc cggggcggtt ctgcgtAAACG TTCAATCCG CTCCCGGGG ATTGTCCTA 1200
ctcaggagag ctgtcaccga caaacaacag ataaaacgaa aggcccagtc ttgcactga 1260
gccttcgtt ttatTTGATG CCTGGCAGTT CCCTACTCTC GCATGGGGAG ACCCCACACT 1320
accatcgccg ctacggcggtt tcacttctga gttcggcatg gggtcagggt ggaccaccgc 1380
gctactgccc ccaggcaaat tctgttttgc cagaccgctt ctgcgttctg attaatctg 1440
tatcaggctg aaaatcttct ctcatccgc AAAACAGGAT CCAATTATGG CAGATCAATG 1500
agcttcacag acacaatatac agggacattt gtttagttt tcacaatttt atcttccaga 1560
tgtctgtcaa agggaaagcat catgatggct tctccgcctt ttcccttacg gccaacctgc 1620
atagttgcaa tggtaatatac attatctccg agaatacgtc ctactcggcc gatgacacct 1680
gttgtatctt gatgtggat atacaccaag tgaccagtgc gataaaaatc aatattaaat 1740
ccattgtatct cgacaattcg ttctccgaaa tgaggaatat acgtggccgt tacagtaaag 1800
gtgcgtcggt ctccgtcact tttacgctg atgcagttat cgtatccaga ttccggaaag 1860
gaaattttt cactgaagct aatgcgcgt tctttgcga caccggcatttgc gatgacacct 1920
ttaacagtag agtctacgcg cggtttaaa aagcctgaca gaagggtttt tgtaatgaac 1980
gatgtttcaa gtttagcaat tgcgttca tattgaatgg caacatcctg tactgttct 2040
ttcgttccact gtcgtataaag gtcgttccatt ttccgttca tttgtggta aggcttaatt 2100
tttagcaattt catctttgtt catggcaggc aggttgcata gtcgtatgc aggcaggcct 2160

tttgcgaact gcagaacttc ttctgacact tgggcggcga cattgagctg tgcttcttc 2220
 gttgatgctc ccaagtgagg agtggcaatg actaatggat gatcaacaag tttgttgtca 2280
 actggcggtt cgacttcgaa aacgtcaagc gctgctccc caacatgcc 2340
 gcttcgagaa gtgctgttc atcgataatt ccgcctcgcc cacagttat taagcgaacg 2400
 cctttttcg ttttgcata cgtttctta ttcaataaagc cttttgttc ttttgttaaa 2460
 ggcgtgtgaa cggtaatgtat atccgcactt tcaagcactt cttcaaatgt acggctgtt 2520
 acggcgattt tttcgctct ttcttccgtt aagaaaggat caaaaacgtg cacagtcata 2580
 ccgaacgctc ctgcacgctg tgcaatttca ttccgatttcc ggcctaattcc tacaatacca 2640
 agcgttttc cataaagctc tgaaccgaca taagctgtgc ggttccactc tctggatttc 2700
 actgagatata tagcctgcgg aatgtgtctc attaaagaag agatcattgc aaatgttatgc 2760
 tcagctgtcg aaatgggtt gccgttcgga gcattgatca cgattacccc gtgttcgta 2820
 gcctcatcaa tatcgatatt atcgacaccg acaccggctc ttccgacaat ttttaaagaa 2880
 gtcattttgt tgaaaaggctt ttctgttact ttgtcgcc ttgcaccaa aagagcatca 2940
 aaagtatgtaa attcatcttc tgcatctgct acgaaaaattt gaacgattt aataaagtct 3000
 gattcaataa gtggctgtaa accgtcggtt ctcattttgt ctgagaccaa tactcgaaac 3060
 atgttttctc ctccctctaga gctcctgtct gttgttaaga ttattataacc acacccgtta 3120
 gataaaagtca acaactttt gaaaaatttt tcaggaattt tagcagaggt tttctggat 3180
 gtagaacaaa acatcttcc gctttgtgc ttttaggata ttttcttgaa aagctaggta 3240
 ggcctcgagt tatggcagtt ggtaaaaagg aaacaaaaag accgttttca cacaacacgg 3300
 tcttttgcg ttttttttca cactcacagc cacttttca aaaacccggac agtttcatgc 3360
 cttataactg ctgtttcggt cgacctgcag gcatgcaagc ttgcgaagc ggccggcag 3420
 gcgaggctgg atggccttcc ccattatgat tttctcgct tccggcggca tcggatgcc 3480
 cgcgttgcag gccatgtgtt ccaggcaggt agatgacgac catcagggac agcttcaagg 3540
 atcgctcgct gcttttacca gcctaacttc gatcaactgga ccgtgtatcg tcacggcgat 3600
 ttatggccgc tcggcgagca catggAACGG gttggcatgg attgtaggcg ccgcctata 3660
 ccttgcgtc ctccccgggt tgctcgccg tgcatggagc cggggccacct cgacctgaat 3720
 ggaagccggc ggcacctcgc taacggattt accactccaa gaattggagc caatcaattc 3780
 ttgcggagaa ctgtgaatgc gcaaaaaaac cttggcaga acatatccat cgcgtccgccc 3840
 atctccagca gcccacccg ggcacatctcg ggcagcggtt gtcctggcc acgggtgcgc 3900
 atgatcgtgc ttctgtcggtt gaggacccgg ctaggctggc ggggttgcct tactgttag 3960
 cagaatgaat caccgataacg cgacgcacg tgaagcact gctgctgca aacgtctgcg 4020
 acctgagcaa caacatgaat gttttcggtt ttccgtgttt ctggaaatgtt gggaaacgcgg 4080
 aagtcaacgc cctgcacccat tatgttccgg atctgcacatcg caggatgtcg ctggctaccc 4140
 tgtggAACAC ctacatctgtt attaacaagc cgctggcatt gaccctgtat gattttctc 4200
 tggtcccggc gcatccatac cgccagttgtt ttaccctcac aacgttccaa taacccggca 4260
 tgttcatcat cagtaacccg tttcgatggc atcctctctc gtttcatcg gtttcatcg 4320
 cccatgaaca gaaattcccc cttacacggg ggcacatcgat gacccaaacag gaaaaaaacccg 4380
 cccttaacat ggcccggtt atcagaagcc agacattaac gcttctggag aaactcaacg 4440
 agctggacgc ggtgaacacg gcacacatct gtgaatcgct tcacgaccac gctgatgagc 4500
 tttaccgcag ctgcctcgcc cggttccggat atgacgtgtaa aacacccgttccat cccatgcagg 4560
 tccccggagac ggtcacagct ttgttgcgttccat cggatggccg gggcggccat gacccggccat 4620
 ggcgttcagc ggggttggc ggggttgcggg ggcacccat gacccggccat cgtacggata 4680
 gcgagggttta tactggctta actatgcggc atcagacggc attgtactga gagtgcacca 4740
 tatgcgggtt gaaataccgc acagatgcgtt aaggagaaaa taccgcacatcg ggcgtcttc 4800
 cgcttcctcg ctcaactgact cgctgcgttc ggtcggtcg ctgcggcgag cggatcg 4860
 tcactcaaaag gcggtataac gtttatccac agaatcaggg gataacgcac gaaagaacat 4920
 gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt 4980
 ccataggctc cggcccccgtt acgacatca caaaaatcgatcgatc agagggtggcg 5040
 aaacccgaca ggactataaa gataccaggc gtttccccctt ggaagctccc tcgtgcgttc 5100
 tcctgttccg accctgcgc ttaccggata cctgtccgc ttctccctt cgggaagcgt 5160
 ggcgtttctt catagctcac gctgttaggtt ttcgtttccat cggatcgatcg 5220
 gctgggctgt gtgcacgaaac ccccccgttca gcccggccgc tgccgttccat cggatcg 5280
 tcgttgcgttccat cttatcgccat ctggcggcgat ccactggtaa 5340
 caggattagc agagcgaggat atgttgcggc tgctacagat ttcttgcgttccat cggatcg 5400
 ctacggctac actagaagga cagttttgg tatctgcgttccat cggatcgatcg 5460
 cgaaaaaga gttggtagctt ctgtatccgg caaacaacc accgctggta ggggtgggtt 5520
 ttttgcgttccat cttatcgccat cttatcgccat cggatcgatcg 5580
 ctttctacg ggggttgcgttccat cttatcgccat cggatcgatcg 5640
 gagattatca aaaaggatct tcacccat cttatcgccat cggatcgatcg 5700

aatctaaagt atatatgagt aaacttggtc tgacagttac caatgctta tcagtgaggc 5760
 acctatctca gcgatctgtc tatttcgttc atccatagtt ggcgtactcc ccgtcggtga 5820
 gataactacg atacgggagg gcttaccatc tggccccagt gtcgaatga taccgcgaga 5880
 cccacgctca ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg 5940
 cagaagtggt cctgcaacct tatccgcctc catccagtct attaatttgtt gccggaaagc 6000
 tagagtaagt agttcgccag ttaatagttt ggcacaacgtt gttgccattt ctgcaggcat 6060
 cgtggtgtca cgctcgctgt ttgttatggc ttcatccgc tccgggtccc aacgatcaag 6120
 gcgagttaca tgatccccca tgggtgtcaa aaaagcggtt agtccttcg gtccctccgat 6180
 cgttgctaga agtaagttgg ccgcagtgtt atcactcatg gttatggcag cactgcataa 6240
 ttctcttact gtcatgccat ccgtaaatgt cttttctgtg actggtgagt actcaaccaa 6300
 gtcattctga gaatagtgtt tgccggcacc gagttgtct tgccggcggt caatacgga 6360
 taataccgcg ccacatacga gaactttaaa agtgctcatc attggaaaac gttctccgg 6420
 gcgaaaactc tcaaggatct taccgctgtt gagatccagt tcgtatgtaac ccactcgtgc 6480
 acccaactga tcttcagcat cttttacttt caccagggtt tctgggtgag caaaaacagg 6540
 aaggcaaaat gcccaaaaaa agggataaag ggcgacacgg aaatgttcaa tactcatact 6600
 ctcccttttta caatatttttta gaagcattta tcagggttat tgtctcatga gcggtatacat 6660
 atttgaatgt atttagaaaaa ataaacaaaat aggggttccg cgacacatttc cccgaaaaagt 6720
 gccacacgtac gtctaagaaa ccattattat catgacattta acctataaaa ataggcgtat 6780
 cacgaggccc ttctcgcttc aagaa 6805

<210> 30

<211> 5983

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:plasmid

<400> 30

tgccgcgcta cagggcgcgt ccattcgcca ttcaaggctgc gcaactgttg ggaaggcgaa 60
 tcgggtcgccc cctcttcgtt attacgcccgg ctggcgaaag gggatgtgc tgcaaggcgaa 120
 ttaaatttggg taacgcccagg gttttcccg tcacgcgtt gtaaaacgcac ggccagtgaa 180
 ttgttaatacg actcaactata gggcgaattt gggccgacgt cgcatgctcc cggccgcatt 240
 gggccgggaa tatcaactgtt gcccggcgctt gcagggtcgac catatgggag agcccggatc 300
 caattatggc agatcaatgtt gcttcacaga cacaatatca gggacatttg ttagttttt 360
 cacaatttttta tcttcccgat gtctgtcaaa ggaaagcatc atgatggctt ctccgccttt 420
 ttcccttacgg ccaacctgca tagttgcaat gtaaatatca ttatctccga gaatacgtcc 480
 tactcgcccg atgacacctt ttttatctt atgctggata tacaccaagt gaccagtccg 540
 ataaaaatca atattaaatc cattgatctc gacaattcgt tctccgaaat gaggaatata 600
 cgtagccgtt acagtaaagg tgctgcggc tcctgtcaact ttacgctgt tgcaaggatc 660
 gtatccagat tcagaagagg aaatttttttca actgaagacta atgcccgcgtt cttttgcac 720
 acccccccggca ttgacccat taacagtaga gtctacgcgc ggttttaaaa agcctgacag 780
 aagggttttta gtaatgaacg atgtttcaag ttttagcaattt gtgccttcatt attgaatggc 840
 aacatccgtt actgggttctt tcatgcactg tgatacaagg ctgccaattt ttctgtcaat 900
 ttgtatggtaa ggcttaattt tagcaaaattt atctttgtc atggcaggca ggttgatagc 960
 tgacatgaca ggcaggcctt ttgcgaactg cagaacttct tctgacactt gggcggcgac 1020
 attgagctgt gcttcttcgtt ttgtatgtcc caagtggatca gttggcaatgt ctaatggatg 1080
 atcaacaagt ttgttgtcaaa ctggcggttc gacttgcggaa acgtcaagcg ctgtccccgc 1140
 aacatgcccgg ttttccaaag ctttttagac atctaaatct agtactaaa acaattcattc 1200
 cagtaaaata taatatttttta ttttctccca atcaggcttgc atccccagta agtcaaaaaaa 1260
 tagctcgaca tactgttctt ccccgatatac ctccctgtatc gaccggacgc agaaggcaat 1320
 gtcataccac ttgtccggccc tgccgcttct cccaaatgtca ataaagccac ttactttgcc 1380
 atctttcaca aagatgtgc tgctcccgat gtcggcggtt gaaaagacaa gttcccttc 1440
 gggctttcc gtcattttttttttaaaa aatcatcacatc ctcgcgcggaa tctttttatg gagttttttc 1500
 ttcccttttgc tgcataatcca catcgcccgat atcggttatttca agttaagttat ccaatcgcc 1560
 taagcggtcg tctaagctat tcgtataggg acaatccgtt atgtcgatgg agtggaaagag 1620
 cctgtatgcac tccgcataca gctcgataat ttttcagggtt ctttgcatttcatt cttcataactc 1680
 ttcccgagcaaa aggacgccttcat cggcctcactt catgagcaga ttgctccgac catcatgccc 1740
 ttcaaaatgtc aggacgttttgc gaaacaggcggc ctttccttcc accatagca tcatgtccctt 1800

ttcccgttcc acatcatagg tggcccttt ataccggctg tccgtcattt ttaaatata 1860
gttttcattt tctccacca gtttatatac ctttagagga gacattcctt ccgtatctt 1920
tacgcagcgg tattttcga tcagttttt caattccgt gatattctca ttttagccat 1980
ttattatttc ttccctctt tctacagttt ttaaagatac cccaagaagc taattataac 2040
aagacgaact ccaattcaact gttccttgca ttctaaaacc ttaaataccca gaaaacagct 2100
tttcaaagt tgtttgaaa gttggcgtat aacatagtat cgacggagcc gattttgaaa 2160
ccacaattat gatagaattt acaagctata aggttattgt cctggggttc aagcattagt 2220
ccatgcaagt ttttatgctt tgcccattct atagatatac tgataagcgc gctgcctatg 2280
cctggcccc taaaaatcctt acatacggcg atatctcta tataaaagat atattatctt 2340
atcagtattt tcaatatattt caaggcaatc tgcctcctca tcctcttcat cctttcgctc 2400
ttggtagctt ttaaatatg gcgcctcata gagtaattct gtaaagggtcc aatttcgtt 2460
ttcatacctc ggtataatct tacctatcac ctcaaattgt tcgctgggtt tatttcgtt 2520
tgccgtattt ttccttacg catctgtgcg gtatttcacg tcgacgcggc cgccatggcc 2580
gcgggatccc ggtaccgaaa catcgtaga tttccctca aattgacaaa ctaaatatct 2640
gataatttaa catatttca aaagagtgtc aacgtgtatt gacgcagtaa aggataaaag 2700
taaaggctaa taaatcaatg atctgacagc ttgcaggtaa tatatttaat ttgaagcaat 2760
tctctataca gccaaccagt tatcgtttattt aatgttaatta aatttcatat gatcaatctt 2820
cggggcaggg taaaaattccc taccggcggt gatgagccaa tggctctaag cccgcgagct 2880
gtcttacag caggattcgg ttagattccg gagccgacag tacagtctgg atgggagaag 2940
atggaggttc ataagcgttt tggaaattgaa ttttccaaac gtttcttgc cttagcttaat 3000
tttcgaaacc cgccttttattt atatgaagcg gtttttttattt tggctggaaa agaaccttc 3060
cgtttgcgag taagatgtga tcgaaaagga gagaatgaag tgaaagtaaaa aaaatttagtt 3120
gtggtcagca tgctgagcag cattgcattt gttttgatgc tgtaaattt cccgttccg 3180
ggcttccgg attatttaaa aatcgattttt agcgacgttc ccccaattat tgccattctg 3240
atttacggac ctttggcggg atcactagag ggctccaaac gcgttggatg catagcttga 3300
gtattctata gtgtcaccta aatagcttgg cgtaatcatg gtcatacgatg tttctgtgt 3360
gaaattgtta tccgctcaca attccacaca acatacgacg cggaaacata aagttaaag 3420
cctgggtgc ctaatgatgc agctaactca cattaattgc gttgcgtca ctgcccgtt 3480
tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc gcggggagag 3540
gcggtttgcg tattgggcgc tcttcgcctt cctcgctcac tgactcgctg cgctcggtcg 3600
ttccgctgcg gcgagcggta tcagctact caaaggcgtt aatacggta tccacagaat 3660
caggggataa cgcaggaaag aacatgttag caaaaggcca gaaaaaggcc aggaaccgtt 3720
aaaaggccgc gttgctggcg ttttcgata ggctccccc ccctgacgag catcacaaaa 3780
atcgacgctc aagtcaagg tggcggaaacc cgacaggact ataaagatac caggcgttt 3840
ccccttggaaag ctccctcgat cgctctctgt ttccgaccct ggcgttacc ggataacctgt 3900
ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt aggtatctca 3960
gttcgggtgtt ggtcggtcg tccaaagctgg gctgtgtca cgaacccccc gttcagcccg 4020
accgctgcgc cttatccggt aactatcgat ttgagtttcaaa cccggtaaga cacgacttat 4080
cgccactggc agcagccact ggtAACAGGA tttagcagacg gaggtatgtt ggcgggtcta 4140
cagagttctt gaagtgggtt cctaactacg gctacactag aaggacagta ttggatctt 4200
gcgcctgtgtt gaagccagtt accttcggaa aaagagttgg tagcttttgc tccggcaaac 4260
aaaccaccgc tggtagcggg ggttttttgg tttgcaagca gcaaggatcgc cgcagaaaaaa 4320
aagatctca agaagatctt ttgatctttt ctacggggtc tgacgctcag tggaaacgaaa 4380
actcacgtta agggattttt gtcacatggat tatcaaaaaa gatcttcacc tagatctttt 4440
taaattaaaaa atgaagttttt aaatcaatctt aaagtatata ttagttaact tggctgtaca 4500
gttaccaatg cttatcgtt gaggcaccta tctcagcgtt ctgtcttattt cgttcatcca 4560
tagttgcctt actccccgtc gtgtagataa ctacgataacg ggaggggctt ccacatggcc 4620
ccagtgcgtc aatgataccg cgagaccac gtcaccggc tccagattt tcagcaataa 4680
accagccagc cggaggccgc gagcgcagaa gttggcgttc aactttatcc gcctccatcc 4740
agtctattaa ttgttgcggg gaagcttagag taagtagttt gccagttat agtttgcgc 4800
acgttgttgg cattgtaca ggcacatgtgg tgcacgctc gtcgttggat atggcttcat 4860
tcagctccgg ttcccaacga tcaaggcggag ttacatgatc ccccatgttg tgcaaaaaag 4920
cggttagctc cttcggtcctt ccgtatcgat ttcagaatggat gttggccgc gttgttatcac 4980
tcatggttat ggcagcaactg cataattctt ttactgtcat gccatccgtt agatgtttt 5040
ctgtgactgg tgagtagtca accaagtcat tctgagaata cccgcggccgg cgaccgagtt 5100
gctcttgcgc ggcgtcaata cgggataata gttgtatgaca tagcagaact taaaagggtgc 5160
tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgtttagat 5220
ccagttcgat gtaaccact cgtgcacccca actgatcttcc agcatctttt actttcacca 5280
gcgtttctgg gtgagcaaaa acagggagcc aaaatgccgc aaaaaaggaa ataaggccga 5340

cacggaaatg ttgaataactc atactcttcc tttttcaata ttattgaagc atttatcagg 5400
 gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaaa caaatagggg 5460
 ttccgcgcac atttccccga aaagtgccac ctgtatgcgg tgtgaaatac cgcacagatg 5520
 cgtaaggaga aaataccgca tcaggcgaaa ttgtaaacgt taatattttt taaaatttcg 5580
 cgttaaatat ttgttaaatc agctcattt ttaacccaata ggccgaaatc ggcaaaatcc 5640
 cttataaatac aaaagaatag accgagatag ggttgagtgt tgttccagtt tggaacaaga 5700
 gtccactatt aaagaacgtg gactccaacg tcaaaggcgaaa aaaaaccgtc tatcaggcg 5760
 atgcccact acgtgaacca tcacccaaat caagttttt gcggtcgagg tgccgtaaag 5820
 ctctaaatcg gaaccctaaa gggagcccc gathtagc ttgacgggga aagccggcga 5880
 acgtggcgag aaaggaaggg aagaaagcga aaggagcggg cgctagggcg ctggcaagtg 5940
 tagcggtcac gctgchgta accaccacac ccggcgct taa 5983

<210> 31

<211> 7330

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: plasmid

<400> 31

ttgcggccgc ttcgaaagct gtaatataaa aaccttcttc aactaacggg gcaggtagt 60
 gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
 tcattaggcc tatctgacaa ttccgtata gagttcataa acaatcctgc atgataacca 180
 tcacaaacag aatgatgtac ctgtaaagat agcggtaat atattgaatt accttattta 240
 atgaattttc ctgctgtat aatgggtaga aggttaattac tattattatt gatatttaag 300
 ttaaacccag taaatgaagt ccatgaaata atagaaagag aaaaagcatt ttcaggtata 360
 ggtgtttgg gaaacaattt ccccgaaacca ttatatttct ctacatcaga aaggataaaa 420
 tcataaaact ctttgaagtc attcttaca ggagtccaaa taccagagaa tgtttagat 480
 acaccatcaa aaattgtata aagtggctct aacttatccc aataacctaa ctctccgtcg 540
 ctattgtac acgttctaaa agctgtatTTT gagtttatca cccttgtcac taagaaaata 600
 aatgcagggt aaaatttata tccttcttgc tttatgtttc ggtataaaaac actaatatca 660
 atttctgtgg ttatactaaa agtcgtttgt tggttcaat aatgattaaa tatctttttt 720
 ctcttccaaat tgcataatc aatttttata aagttcattt gatatgcctc ctaaattttt 780
 atctaaagtg aatttaggag gttacttgc ctgctttctt cattagaatc aatccttttt 840
 taaaagtcaa tattactgtt acataaataat atattttaaa aatatccac ttatccaaat 900
 tttcggttgc tgaactaatg ggtgttttag ttgaagaata aagaccacat taaaaaatgt 960
 ggtctttgt gttttttaa aggattttag cgtagcgaaa aatcctttc tttcttatct 1020
 tgataataag ggttaactatt gaattcggtt ccaagagttt gtagaaacgc aaaaaggcca 1080
 tccgtcagga tggccttctg cttaaatttgc tgccgttgcgg tttatggcg ggcgtctgccc 1140
 cgcaccctc cggccgttgc ctgcacacg ttcaaatccg ctccggcgatg atttgtccata 1200
 ctcaggagag cgttccaccga caaacaacag ataaaacgaa aggcccagtc ttgcactga 1260
 gccttcgtt ttatgttgc cctggcgtt ccctacttc gcatggggag accccacact 1320
 accatcgccg ctacggcgatg tcaatttgc gttccgttgc ggttcagggtt ggaccacccgc 1380
 gctactgcgc ccaggcaaat tctgttttat cagaccgtt ctgcgttctg attaatctg 1440
 tatacggctg aaaatcttct ctcattccgc aaaacaggat ccaattatgg cagatcaatg 1500
 agcttcacag acacaatatc agggacattt gtttagttct tcacaattttt atcttccaga 1560
 tgcgttgc tggaaagcat catgatggct tctccgcctt tttccttacg gccaacctgc 1620
 atagttgcaa tgcataatc attatctccg agaatacgtc ctactcggcc gatgacacact 1680
 gttgtatctt gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc gatgttgc 1740
 ccattgtatc cgacaatttcg ttctccgaaa tgaggaatat acgttagccgt tacagtaaag 1800
 gttgttgc gttgttgc ttttacgttgc atgcgttgc ttttacgttgc atgcgttgc 1860
 gaaattttt cactgaagct aatgcccgt tcttttgcga caccggcgatg attgacactca 1920
 ttaacagtag agtctacgcg cgggtttaaa aagcctgaca gaaggcgatg ttttacgttgc 1980
 gatgttcaat gtttagcaat tgcgttgc ttttacgttgc atgcgttgc atgcgttgc 2040
 ttcatgcact gttgttgc gttgttgc ttttacgttgc atgcgttgc atgcgttgc 2100
 ttagcaattt ctttttgc gttgttgc gttgttgc atgcgttgc atgcgttgc 2160
 ttttgcact gttgttgc gttgttgc atgcgttgc atgcgttgc atgcgttgc 2220
 gttgttgc gttgttgc gttgttgc atgcgttgc atgcgttgc atgcgttgc 2280

actggcggtt cgacttcgaa aacgtcaagc gctgctccc caacatgcc 2340
 gcttcgagaa gtgctgcttc atcgataatt ccgcctcgcg cacagttaat taagcgaacg 2400
 cctttttcg ttttgcattt cgtttcttta ttcaataagc cttttgtttc ttttgttaaa 2460
 ggcgtgtgaa cggtaatgtat atccgcactt tcaagcactt cttcaaatgt acggctgttt 2520
 acggcgattt ttttcgtct ttcttccgtt aagaaaggat caaaaacgtg cacagtata 2580
 ccgaacgctc ctgcacgctg tgcaatttca cttccgattt ggcctaattcc tacaatacca 2640
 agcgttttc cataaagctc tgaaccgaca taagctgtgc ggttccactc tctggattttc 2700
 actgagatatt tagcctgcgg aatgtgtctc attaaagaag agatcattgc aaatgtatgc 2760
 tcagctgtcg aaatgggttt gccgttcgga gcattgatca cgattacccc gtgttcgta 2820
 gcctcatcaa tatogatatt atcgacacccg acaccggctc ttccgacaat tttaaagaa 2880
 gtcattttgt tgaaaaggtc ttctgttact tttgtcgcc ttcgcaccaa aagagcatca 2940
 aaagtatgtt attcatcttc tgcatctgtc acgtttttt gaacgatttc aataaagtct 3000
 gattcaataa gtggctgtaa accgtcggtt ctcattttgt ctgagaccaa tactcgaac 3060
 atgtttctc ctccctctaga gcttcgtct gttgttaaga ttattatacc acacccgtta 3120
 gataaagtca acaactttt gcaaaatttt tcaggaattt tagcagaggt tggtctggat 3180
 gtagaacaaa acatcttcc gctcttggtc tgtaggata tctttcttgg aagcttagta 3240
 ggctcgttgt tatggcagtt gttaaaagg aaacaaaag accgtttca cacaacacgg 3300
 tcttttgcg tttcttttta cagtcacagc cacttttgc aaaaacccggac agcttcatgc 3360
 cttataactg ctgtttcggt cgacgaaaca tcgttagatt tcctcctaaa ttgacaaact 3420
 aaatatctga taatttaaca tattctcaaa agagtgtcaa cgtgtattga cgcagtaaag 3480
 gataaaagta aagcctaata aatcaatgtat ctgacagctt gcaggtataa tatttaattt 3540
 gaagcaattc tctatacagc caaccagttt tcgtttataa tgtaattaaa tttcatatga 3600
 tcaatctcg gggcagggtt aaattcccta ccggcggtga tgagccaatg gctctaagcc 3660
 cgcgagctgt ctttacagca ggattcggtg agattccgg a gccgacagta cagtctggat 3720
 gggagaagat ggagggtcat aagcgtttt aatttgaatt tttcaaacgt ttcttgcct 3780
 agcctaattt tcgaaacccc gttttatattt atgaagcggt ttttttattt gctggaaaag 3840
 aaccttccg ttttcgagta agatgtgatc gaaaaggaga gaatgaagtg aaagtaaaaa 3900
 aattagttgt ggtcagcatg caagcttcgc gaagcggccg cgcacgcgag gctggatggc 3960
 ctccccattt atgattttc tcgcttccgg cggtatcgatc atgcccgcgt tgcaggccat 4020
 gctgtccagg caggttagatc acgaccatca gggacagctt caaggatcgatc tgcgcgtct 4080
 taccagccta acttcgatca ctggaccgtc gatcgatc acgatattatc cccgcctcgcc 4140
 gagcacatgg aacgggttgg catggattgt aggccgcgc ctataccttgc tctgcctccc 4200
 cgcgttgcgt cgccgtgcgtt ggagccgggc cacctcgacc tgaatggaa cccggccgcac 4260
 ctcgctaacg gattcaccac tccaagaattt ggagccaaatc aattcttgcg gagaactgtg 4320
 aatcgcaaa ccaacccttgcg cagaacata tccatcgatc cccgcctc cagcagccgc 4380
 acgcggcgca tctcggcgatc cgttgggtcc tggccacggg tgcgcgtatc cgtgcctctg 4440
 tcgttggatc cccggcttggatc ctggcggttgc tgccttactt gttttttttt gtaatcaccg 4500
 atacgcgagc gaacgtgaag cgactgtgc tgcaaaacgt ctgcgcacctg agcaacaaca 4560
 tgaatggtct tcggtttccg tggatcgatc agtctggaaa cgcggaaatc agcgccttc 4620
 accattatgt tccggatctg catcgatc tgcgttgc taccctgtgg aacacctata 4680
 tctgttattaa cgaagcgctg gatttgcattt tgatgtattt ttctctggatc cccggccatc 4740
 cataccgcca gttgtttacc ctacaacatc tccatcgatc gggcatgttc atcatcgatc 4800
 acccgatcgatc tgcgttgc tctcgttgc atcgatc taccatcgatc taccatcgatc 4860
 tcccccattt acggaggatc caagtgcacca aacaggaaaa aaccgcctt aacatggccc 4920
 gctttatcg aagccagaca ttaacgcctt tggagaaaactt caacgcgtt gacgcggatg 4980
 aacaggcaga catctgtgaa tcgcttcacg accacgttgc tgacgttttgc cgcagctgccc 5040
 tcgcgcgttt cggatcgatc ggtggaaaacc tctgcacatc gcaatcgatc gagacggatc 5100
 cagcttgcgt gtaagcgat gccggggatc gacaaggccg tcaggccgcg tcagccgggt 5160
 ttggcggttgc tccggccgc tccatcgatc agtgcgttgc cgtatcgatc gttgtatactg 5220
 gcttaactat cggatcgatc agcagattgtt actgagatgtt caccatcgatc ggtgtgaaat 5280
 accgcacaga tgcgttgc tggatcgatc gaaaatcgatc catcgatc taccatcgatc 5340
 tgactcgctg cgctcggtcg ttccgttgcg gcgagccgtt tgcgttgc tcaaggccgt 5400
 aatacggtt tccatcgatc cggggatc gcaaggccg aacatcgatc cggatcgatc 5460
 gcaaaaaggcc aggaacccgtt aaaaaggccgc gttgttgc tttttccatc ggatcgatc 5520
 ccctgacgatc catcacaatcc atcgatc tgcgttgc aatcgatc taccatcgatc 5580
 ataaagatatac caggcgatc cccctgttgc tccatcgatc cgcgttgc ttcgcaccct 5640
 gcccgttacc ggatcgatc cccctgttgc tccatcgatc cgcgttgc ttcgcaccct 5700
 ctacacgtgtt aggtatctca gttcggttgc ggtcgatc tccatcgatc taccatcgatc 5760
 cgaacccccc gttcgatc tccatcgatc cccctgttgc tccatcgatc taccatcgatc 5820

cccggttaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc 5880
gaggatgtt ggcggtgcta cagagttctt gaagtggtgg ccttaactacg gctacactag 5940
aaggacagta tttggtatct gcgtctgtc gaagccagtt accttcggaa aaagagttgg 6000
tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttt tttgcaagca 6060
gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatcttt ctacggggtc 6120
tgacgcttag tggAACGAAA actcacgtt aaggattttt gtcatgagat tatcaaaaag 6180
gatcttcacc tagatcctt taaattaaaa atgaagttt aaatcaatct aaagtatata 6240
tgagtaaact tggctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat 6300
ctgtcttattt cgttcatcca tagttgcctg actccccgtc gtgttagataa ctacgataacg 6360
ggagggctta ccattctggcc ccagtgtgc aatgataccg cgagacccac gctcacccgc 6420
tccagattt tcagcaataa accagccagc cggaaggccc gagcgcagaa gtggcctgc 6480
aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagcttagag taagtagttc 6540
gccagttaat agtttgcgc aagtgttgc cattgtgc a ggcacatcgat tgcgtcc 6600
gtcgtttggatggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc 6660
ccccatgttg tgcaaaaaaag cggttagctc cttcggcctt ccgtatcggt tcagaagtaa 6720
gttggccgca gtgttacac tcatggttat ggcacactg cataattctc ttactgtcat 6780
gccatccgta agatgcttt ctgtgactgg tgagtactca accaagtcat tctgagaata 6840
gtgtatgcgg cgaccgagtt gctcttgcgg ggcgtcaata cgggataata ccgcgccaca 6900
tagcagaact taaaaggatgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag 6960
gatcttaccg ctgttgagat ccagtgcgtat gtaacccact cgtgcaccca actgatcttc 7020
agcatcttt acttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc 7080
aaaaaaggga ataagggcga cacggaaatg ttgaataactc atactcttcc ttttcaata 7140
ttatttgaaggc atttatcagg gttattgtct catgagcgga tacatattt aatgtattta 7200
aaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgcac ctgacgtcta 7260
agaaaccatt attatcatga cattaaccta taaaatagg cgtatcacga ggcccttcg 7320
tcttcaagaa 7330

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21336

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12P 13/04; C12N 9/02, 9/10, 9/88, 1/20, 15/00; C07H 21/04
 US CL : 435/106, 189, 193, 232, 252.3, 320.1; 536/23.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 435/106, 189, 193, 232, 252.3, 320.1; 536/23.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/21772 A2 (OMNIGENE BIOPRODUCTS) 29 March 2001 (29.03.2001), see entire document.	1-10, 16-22, 29, 36-38, 42-49

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 22 August 2002 (22.08.2002)	Date of mailing of the international search report 13 NOV 2002
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer <i>Tekchand Saidha</i> Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/21336

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claim Nos.: 11-15, 23-28, 30-35, 39-41
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.